var title_f14_62_15328="Stenosis venous anastomosis";
var content_f14_62_15328=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F52331&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F52331&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 488px\">",
"   <div class=\"ttl\">",
"    Stenosis at the venous anastomosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 468px; height: 206px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The appearance of the lesion prior to therapy is shown on the left. Its appearance following angioplasty is on the right.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Gerald Beathard, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_62_15328=[""].join("\n");
var outline_f14_62_15328=null;
var title_f14_62_15329="Erythema multiforme extrem PI";
var content_f14_62_15329=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F66481&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F66481&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Erythema multiforme",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 325px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Erythema multiforme causes many red spots to appear on the body. The spots often have a dark center surrounded by pale red rings, like a target or bull's-eye.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_62_15329=[""].join("\n");
var outline_f14_62_15329=null;
var title_f14_62_15330="Petechiae";
var content_f14_62_15330=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F73905&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F73905&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Petechiae",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 347px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Leslie Raffini, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_62_15330=[""].join("\n");
var outline_f14_62_15330=null;
var title_f14_62_15331="Vitamin D deficiency";
var content_f14_62_15331=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Vitamin D deficiency (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?14/62/15331/contributors\">",
"       Author",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/62/15331/contributors\" id=\"au6176\">",
"       Marc K Drezner, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?14/62/15331/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/62/15331/contributors\" id=\"se178\">",
"       Clifford J Rosen, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?14/62/15331/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/62/15331/contributors\" id=\"de1470\">",
"       Jean E Mulder, MD",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"UTD.htm?14/62/15331?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      INTRODUCTION",
"     </span>",
"    </p>",
"    <p>",
"     Vitamin D plays an important role in many places throughout the body, including the development and calcification of the bones.",
"    </p>",
"    <p>",
"     Adequate exposure to sunlight and the use of dairy products with vitamin D have significantly reduced the incidence of vitamin D deficiency. However, vitamin D deficiency is still a common problem in many populations, particularly older adults.",
"    </p>",
"    <p>",
"     This topic reviews the major causes of vitamin D deficiency, including how it is diagnosed and treated, and safe ways to prevent vitamin D deficiency.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      WHAT IS VITAMIN D?",
"     </span>",
"    </p>",
"    <p>",
"     Vitamin D is an oil-soluble vitamin that has several important functions in the body:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       It helps to absorb dietary calcium and phosphorus from the intestines.",
"      </li>",
"      <li>",
"       It suppresses the release of parathyroid hormone, a hormone that causes bone resorption.",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     Through these actions, vitamin D keeps the calcium and phosphate levels in the blood normal, thereby promoting bone health. Vitamin D may have other benefits, such as improving muscle and immune function, but these areas require more research.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H3\">",
"     <span class=\"h2\">",
"      Natural sources of vitamin D",
"     </span>",
"     &nbsp;&mdash;&nbsp;Vitamin D is made in the skin under the influence of sunlight. The amount of sunlight needed to synthesize adequate amounts of vitamin D varies, depending upon the person's age, skin color, sun exposure, and underlying medical problems. The production of vitamin D from the skin decreases with age. In addition, people who have darker skin need more sun exposure to produce adequate amounts of vitamin D, especially during the winter months.",
"    </p>",
"    <p>",
"     Another important source of vitamin D is foods, where it may occur naturally (in fatty fish, cod-liver oil, and [to a lesser extent] eggs). In the United States, commercially fortified cow's milk is the largest source of dietary vitamin D, containing approximately 100 international units of vitamin D per 8 ounces. Vitamin D intake can be estimated by multiplying the number of cups of milk consumed per day by 100 (two cups milk = 200 international units vitamin D). In other parts of the world, cereals and bread products are often fortified with vitamin D.",
"    </p>",
"    <p>",
"     Although vitamin D is found in cod liver oil, some fish oils also contain high doses of vitamin A. Excessive vitamin A intake can be associated with side effects, including liver damage and fractures.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H4\">",
"     <span class=\"h1\">",
"      CAUSES OF VITAMIN D DEFICIENCY",
"     </span>",
"    </p>",
"    <p>",
"     The main reasons for low levels of vitamin D are:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Lack of vitamin D in the diet, often in conjunction with inadequate sun exposure",
"      </li>",
"      <li>",
"       Inability to absorb vitamin D from the intestines",
"      </li>",
"      <li>",
"       Inability to process vitamin D due to kidney or liver disease",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5\">",
"     <span class=\"h2\">",
"      Inadequate intake",
"     </span>",
"     &nbsp;&mdash;&nbsp;Infants, children, and elderly adults are at risk for low vitamin D levels because of inadequate vitamin D intake. Human breast milk contains low levels of vitamin D and most infant formulas do not contain adequate vitamin D. Elderly adults often do not consume enough vitamin D rich foods, and even when they do, absorption may be limited.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H6\">",
"     <span class=\"h2\">",
"      Inadequate sun exposure",
"     </span>",
"     &nbsp;&mdash;&nbsp;Parents of infants and children are often advised to keep their child out of the sun, which reduces vitamin D synthesis from the skin. Exposure to the sun is not recommended as a source of vitamin D for infants and children due to the potential long-term risks of skin cancer. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?18/30/18913?source=see_link\">",
"      \"Patient information: Sunburn (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     Adults who have limited sun exposure are also at increased risk of vitamin D deficiency, especially if their skin is dark. In addition, reduced amounts of vitamin D are made in the skin and stored in the body as we age. This is especially true in the winter months in some northern areas, such as Boston, Massachusetts and Edmonton, Alberta, where the skin virtually ceases to produce vitamin D between October and April. In the summer months, the use of sunscreen limits vitamin D synthesis.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7\">",
"     <span class=\"h2\">",
"      Diseases or surgery that affect fat absorption",
"     </span>",
"     &nbsp;&mdash;&nbsp;Certain diseases affect the body's ability to absorb adequate amounts of vitamin D through the intestinal tract. Examples of these include celiac disease, Crohn's disease, and cystic fibrosis.",
"    </p>",
"    <p>",
"     Surgery that removes or bypasses portions of the stomach or intestines can also lead to low vitamin D levels. An example of this type of surgery is gastric bypass. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?9/37/9811?source=see_link\">",
"      \"Patient information: Weight loss surgery (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H8\">",
"     <span class=\"h2\">",
"      Kidney and liver disease",
"     </span>",
"     &nbsp;&mdash;&nbsp;The liver and kidney have important enzymes that change vitamin D from the sun or food to the biologically active form of vitamin D. People with chronic kidney and liver disease are at increased risk of low active vitamin D levels because they lack these enzymes.",
"    </p>",
"    <p>",
"     Less common causes of vitamin D deficiency include familial diseases that impair the enzymes in the liver or kidney that create the biologically active form of the vitamin. This results in inadequate amounts of active vitamin D.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H9\">",
"     <span class=\"h1\">",
"      POTENTIAL COMPLICATIONS OF VITAMIN D DEFICIENCY",
"     </span>",
"    </p>",
"    <p>",
"     The most serious complications of vitamin D deficiency are low blood calcium (hypocalcemia), low blood phosphate (hypophosphatemia), rickets (softening of the bones during childhood), and osteomalacia (softening of the bones in adults). However, these complications have become less common over time because many foods and drinks have added vitamin D.",
"    </p>",
"    <p>",
"     \"Subclinical\" vitamin D deficiency or vitamin D insufficiency is common, and is defined as a lower than normal vitamin D level that has no visible signs or symptoms. However, vitamin D insufficiency is associated with reduced bone density (osteopenia or osteoporosis), a mild decrease of the blood calcium level, elevated parathyroid hormone (which accelerates bone resorption), an increased risk of falls, and possibly fractures, all of which can seriously affect a person's quality of life.",
"    </p>",
"    <p>",
"     Thus, identifying and treating vitamin D insufficiency or deficiency is important to maintain bone strength. Treatment may even improve the health of other body systems, such as the immune, muscular, and cardiovascular systems, although more research is needed in these areas.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H10\">",
"     <span class=\"h1\">",
"      DIAGNOSIS OF VITAMIN D DEFICIENCY",
"     </span>",
"    </p>",
"    <p>",
"     A low vitamin D level can be diagnosed with a blood test called 25 hydroxyvitamin D or 25OHD (OH = hydroxy, D = vitamin D). Although there is no formal definition of vitamin D deficiency, some groups use the following values in adults:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       A normal level of vitamin D is defined as a 25OHD concentration greater than 30",
"       <span class=\"nowrap\">",
"        ng/mL",
"       </span>",
"       (75",
"       <span class=\"nowrap\">",
"        nmol/L).",
"       </span>",
"      </li>",
"      <li>",
"       Vitamin D insufficiency is defined as a 25OHD concentration of 20 to 30",
"       <span class=\"nowrap\">",
"        ng/mL",
"       </span>",
"       (50 to 75",
"       <span class=\"nowrap\">",
"        nmol/L).",
"       </span>",
"      </li>",
"      <li>",
"       Vitamin D deficiency is defined as a 25OHD level less than 20",
"       <span class=\"nowrap\">",
"        ng/mL",
"       </span>",
"       (50",
"       <span class=\"nowrap\">",
"        nmol/L).",
"       </span>",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11\">",
"     <span class=\"h2\">",
"      Who needs testing for vitamin D?",
"     </span>",
"     &nbsp;&mdash;&nbsp;Testing for vitamin D deficiency or insufficiency is not recommended for everyone, but may be advised for people who are home-bound or in a long-term care facility (eg, nursing home), if the person has a medical condition that increases the risk of vitamin D deficiency or insufficiency, and for anyone with osteoporosis or a past history of a low-trauma fracture (eg, fracture after fall from standing), low blood calcium (hypocalcemia) or phosphate (hypophosphatemia). (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?1/29/1491?source=see_link\">",
"      \"Patient information: Bone density testing (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?24/49/25366?source=see_link\">",
"      \"Patient information: Osteoporosis prevention and treatment (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H12\">",
"     <span class=\"h1\">",
"      TREATMENT OF VITAMIN D DEFICIENCY",
"     </span>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H13\">",
"     <span class=\"h2\">",
"      Vitamin D supplements",
"     </span>",
"     &nbsp;&mdash;&nbsp;There are many types of vitamin D preparations available for the treatment of vitamin D deficiency or insufficiency. The two commonly available forms of vitamin D supplements are ergocalciferol (vitamin D2) and cholecalciferol (vitamin D3). We suggest vitamin D3 when possible, rather than vitamin D2, because vitamin D3 is the naturally occurring form of the vitamin and it may raise vitamin D levels more effectively.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H14\">",
"     <span class=\"h3\">",
"      Dosing",
"     </span>",
"     &nbsp;&mdash;&nbsp;The recommended dose of vitamin D depends upon the nature and severity of the vitamin D deficiency.",
"    </p>",
"    <p>",
"     In people who do not have problems absorbing vitamin D:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       In people whose 25OHD is &lt;20",
"       <span class=\"nowrap\">",
"        ng/mL",
"       </span>",
"       (50",
"       <span class=\"nowrap\">",
"        nmol/L),",
"       </span>",
"       treatment usually includes 50,000 international units of vitamin D2 or D3 by mouth once or more per week for six to eight weeks, and then 800 to 1000 (or more) international units of vitamin D3 daily thereafter.",
"      </li>",
"      <li>",
"       In people whose 25OHD is 20 to 30",
"       <span class=\"nowrap\">",
"        ng/mL",
"       </span>",
"       (50 to 75",
"       <span class=\"nowrap\">",
"        nmol/L),",
"       </span>",
"       treatment usually includes 800 to 1000 international units of vitamin D3 by mouth daily, usually for a three month period. However, many individuals will need higher doses. The \"ideal\" dose of vitamin D is determined by testing the individual's 25OHD level, and increasing the vitamin D dose if the level is not within normal limits. Once a normal level is achieved, continued therapy with 800 international units of vitamin D per day is usually recommended.",
"      </li>",
"      <li>",
"       In infants and children whose 25OHD is &lt;20",
"       <span class=\"nowrap\">",
"        ng/mL",
"       </span>",
"       (50",
"       <span class=\"nowrap\">",
"        nmol/L),",
"       </span>",
"       treatment usually includes 1000 to 5000 international units of vitamin D2 by mouth per day (depending on the age of the child) for two to three months.",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     In people who have diseases or conditions that prevent them from absorbing vitamin D normally (eg, kidney or liver disease), the recommended dose of vitamin D will be determined on an individual basis.",
"    </p>",
"    <p>",
"     In people whose vitamin D level is normal (&gt;30",
"     <span class=\"nowrap\">",
"      ng/mL",
"     </span>",
"     [&ge;75",
"     <span class=\"nowrap\">",
"      nmol/L]),",
"     </span>",
"     a dose of 800 international units of vitamin D per day is usually recommended. (See",
"     <a class=\"local\" href=\"#H18\">",
"      'Prevention of vitamin D deficiency'",
"     </a>",
"     below.)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H15\">",
"     <span class=\"h2\">",
"      Do I need other vitamins or minerals?",
"     </span>",
"     &nbsp;&mdash;&nbsp;During treatment for vitamin D deficiency, it is important to consume at least 1000 mg of calcium per day for premenopausal women and men and 1200 mg per day for postmenopausal women.",
"    </p>",
"    <p>",
"     Calcium can be found in food sources (",
"     <a class=\"graphic graphic_table graphicRef67824 \" href=\"UTD.htm?28/58/29611\">",
"      table 1",
"     </a>",
"     ) or dietary supplements (",
"     <a class=\"graphic graphic_table graphicRef70454 \" href=\"UTD.htm?36/37/37468\">",
"      table 2",
"     </a>",
"     ). (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?22/60/23491?source=see_link\">",
"      \"Patient information: Calcium and vitamin D for bone health (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H16\">",
"     <span class=\"h2\">",
"      Monitoring",
"     </span>",
"     &nbsp;&mdash;&nbsp;A blood test is recommended to monitor blood levels of 25OHD three months after beginning treatment. The dose of vitamin D may need to be adjusted based on these results.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H17\">",
"     <span class=\"h2\">",
"      Side effects",
"     </span>",
"     &nbsp;&mdash;&nbsp;Side effects of vitamin D are uncommon unless the 25OHD level becomes very elevated (&gt;100",
"     <span class=\"nowrap\">",
"      ng/mL",
"     </span>",
"     or 250",
"     <span class=\"nowrap\">",
"      mmol/L)",
"     </span>",
"     and the person is taking high dose calcium supplements. However, it is important to follow dosing instructions closely and to avoid taking multiple products that contain vitamin D (eg, multivitamin and vitamin D).",
"    </p>",
"    <p>",
"     If 25OHD levels do become very elevated, complications such as high blood calcium levels or kidney stones can develop.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H18\">",
"     <span class=\"h1\">",
"      PREVENTION OF VITAMIN D DEFICIENCY",
"     </span>",
"    </p>",
"    <p>",
"     As mentioned previously, the amount of vitamin D you need per day to maintain a normal level of 25OHD depends upon your skin color, sun exposure, diet, and underlying medical conditions.",
"    </p>",
"    <p>",
"     In general, adults are advised to take a supplement containing 800 international units of vitamin D per day to maintain a normal vitamin D level. Older people who are confined indoors may have vitamin D deficiency even at this intake level. (See",
"     <a class=\"local\" href=\"#H13\">",
"      'Vitamin D supplements'",
"     </a>",
"     above.)",
"    </p>",
"    <p>",
"     All infants and children are advised to take a vitamin D supplement containing 400 international units of vitamin D, starting within days of birth. For infants and children, vitamin D is included in most non-prescription infant multivitamin drops. In some countries, it is possible to buy infant drops that contain only vitamin D. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?1/19/1333?source=see_link\">",
"      \"Patient information: Breastfeeding guide (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?40/32/41476?source=see_link\">",
"      \"Patient information: Starting solid foods during infancy (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     Exposure to the sun or tanning beds is not recommended as a source of vitamin D because of the risk of skin cancer.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H19\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H3498674443\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11568380\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?10/45/10962?source=see_link\">",
"      Patient information: Vitamin D deficiency (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?34/58/35746?source=see_link\">",
"      Patient information: Osteoporosis (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?35/12/36034?source=see_link\">",
"      Patient information: Calcium and vitamin D for bone health (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?39/38/40546?source=see_link\">",
"      Patient information: Vitamin supplements (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?12/57/13202?source=see_link\">",
"      Patient information: Vitamin D for babies and children (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11568425\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?18/30/18913?source=see_link\">",
"      Patient information: Sunburn (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?9/37/9811?source=see_link\">",
"      Patient information: Weight loss surgery (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?1/29/1491?source=see_link\">",
"      Patient information: Bone density testing (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?24/49/25366?source=see_link\">",
"      Patient information: Osteoporosis prevention and treatment (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?22/60/23491?source=see_link\">",
"      Patient information: Calcium and vitamin D for bone health (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?1/19/1333?source=see_link\">",
"      Patient information: Breastfeeding guide (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?40/32/41476?source=see_link\">",
"      Patient information: Starting solid foods during infancy (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H20\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/25/15767?source=see_link\">",
"      Causes of hypophosphatemia",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/18/38184?source=see_link\">",
"      Causes of vitamin D deficiency and resistance",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/54/27494?source=see_link\">",
"      Epidemiology and etiology of osteomalacia",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/9/11416?source=see_link\">",
"      Clinical manifestations, diagnosis, and treatment of osteomalacia",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/51/43829?source=see_link\">",
"      Endocrine dysfunction in the nephrotic syndrome",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/25/24984?source=see_link\">",
"      Etiology of hypocalcemia in adults",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/12/31946?source=see_link\">",
"      Geriatric nutrition: Nutritional issues in older adults",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/3/39990?source=see_link\">",
"      Overview of vitamin D",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/50/18218?source=see_link\">",
"      Pathogenesis of renal osteodystrophy",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/21/3417?source=see_link\">",
"      Treatment of vitamin D deficiency in adults",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Mayo Clinic",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.mayoclinic.com/health/vitamin-d/NS_patient-vitamind\">",
"      www.mayoclinic.com/health/vitamin-d/NS_patient-vitamind",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Institutes of Health Office of Dietary Supplements",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://ods.od.nih.gov/factsheets/vitamind.asp\">",
"      file://ods.od.nih.gov/factsheets/vitamind.asp",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       American Academy of Dermatology",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.aad.org/media/background/factsheets/fact_vitamind.htm\">",
"      www.aad.org/media/background/factsheets/fact_vitamind.htm",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Osteoporosis Foundation",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nof.org/aboutosteoporosis/prevention/healthyliving\">",
"      www.nof.org/aboutosteoporosis/prevention/healthyliving",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"UTD.htm?14/62/15331/abstract/1-3\">",
"      1-3",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 8, 2013.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"UTD.htm?14/62/15331?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/62/15331/abstract/1\">",
"      Misra M, Pacaud D, Petryk A, et al. Vitamin D deficiency in children and its management: review of current knowledge and recommendations. Pediatrics 2008; 122:398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/62/15331/abstract/2\">",
"      Holick MF. Vitamin D deficiency. N Engl J Med 2007; 357:266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/62/15331/abstract/3\">",
"      Dawson-Hughes B, Heaney RP, Holick MF, et al. Estimates of optimal vitamin D status. Osteoporos Int 2005; 16:713.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f14_62_15331=[""].join("\n");
var outline_f14_62_15331=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           INTRODUCTION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           WHAT IS VITAMIN D?",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H4\">",
"           CAUSES OF VITAMIN D DEFICIENCY",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H9\">",
"           POTENTIAL COMPLICATIONS OF VITAMIN D DEFICIENCY",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H10\">",
"           DIAGNOSIS OF VITAMIN D DEFICIENCY",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H12\">",
"           TREATMENT OF VITAMIN D DEFICIENCY",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H18\">",
"           PREVENTION OF VITAMIN D DEFICIENCY",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H19\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"       <h1>",
"        GRAPHICS",
"       </h1>",
"       <div id=\"relatedGraphics\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          TABLES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_table\" href=\"UTD.htm?28/58/29611\" title=\"table 1\">",
"           Foods with calcium PI",
"          </a>",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_table\" href=\"UTD.htm?36/37/37468\" title=\"table 2\">",
"           Calcium supplements PI",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f14_62_15332="Abortion by suction curettage";
var content_f14_62_15332=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F78988&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F78988&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 520px\">",
"   <div class=\"ttl\">",
"    Procedure for suction curettage pregnancy termination",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 500px; height: 353px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A-C) Rotation of the suction curette. Little rotation should occur when the instrument is near the uterine wall, to avoid perforation.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_62_15332=[""].join("\n");
var outline_f14_62_15332=null;
var title_f14_62_15333="Acrokeratosis paraneoplastica elbow";
var content_f14_62_15333=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F79717&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F79717&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Acrokeratosis paraneoplastica (Bazex's syndrome)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 323px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Erythematous, scaly plaques are present on the arm.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_62_15333=[""].join("\n");
var outline_f14_62_15333=null;
var title_f14_62_15334="Ferrous sulfate: Pediatric drug information";
var content_f14_62_15334=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Ferrous sulfate: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?36/11/37046?source=see_link\">",
"    see \"Ferrous sulfate: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?5/22/5477?source=see_link\">",
"    see \"Ferrous sulfate: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F170907\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Feosol&reg; [OTC];",
"     </li>",
"     <li>",
"      Fer-In-Sol&reg; [OTC];",
"     </li>",
"     <li>",
"      Fer-iron [OTC];",
"     </li>",
"     <li>",
"      MyKidz Iron 10&trade; [OTC];",
"     </li>",
"     <li>",
"      Slow FE&reg; [OTC];",
"     </li>",
"     <li>",
"      Slow Release [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F170908\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Ferrous Sulfate&reg;;",
"     </li>",
"     <li>",
"      Fer-In-Sol&reg;;",
"     </li>",
"     <li>",
"      Ferodan&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1014035\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Iron Salt",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Mineral, Oral",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block don drugH1Div\" id=\"F11442532\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Neonatal",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     <b>",
"      Multiple concentrations of ferrous sulfate oral liquid exist; close attention must be paid to the concentration when ordering and administering ferrous sulfate; incorrect selection or substitution of one ferrous sulfate liquid for another without proper dosage volume adjustment may result in serious over- or underdosing.",
"     </b>",
"     Dose expressed in terms of",
"     <b>",
"      elemental",
"     </b>",
"     iron:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Recommended daily allowance of iron: 5 mg elemental iron",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Premature neonates: Treatment and prevention of iron deficiency: 2-4 mg elemental iron/kg/day divided every 12-24 hours (maximum dose: 15 mg/day) (Baker, 2010)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Term neonates:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Treatment, severe iron deficiency anemia: 4-6 mg elemental iron/kg/day in 3 divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Treatment, mild to moderate iron deficiency anemia: 3 mg elemental iron/kg/day in 1-2 divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Prophylaxis, iron deficiency anemia: 1-2 mg elemental iron/kg/day up to a maximum of 15 mg elemental iron/day.",
"     <b>",
"      Note:",
"     </b>",
"     In healthy, term infants, AAP does not recommend routine additional supplementation of iron be considered until at least 4-6 months of age if breast-fed (full or partial) (Baker, 2010; Schanler, 2011)",
"    </p>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1014062\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?36/11/37046?source=see_link\">",
"      see \"Ferrous sulfate: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     <b>",
"      Multiple concentrations of ferrous sulfate oral liquid exist; close attention must be paid to the concentration when ordering and administering ferrous sulfate; incorrect selection or substitution of one ferrous sulfate liquid for another without proper dosage volume adjustment may result in serious over- or underdosing.",
"     </b>",
"     Dose expressed in terms of elemental iron:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Recommended Daily Allowance: See table.",
"    </p>",
"    <table border=\"1\" frame=\"border\" rules=\"all\">",
"     <caption style=\"text-align:center;\">",
"      Recommended Daily Allowance of Iron :",
"      <b>",
"       (Dosage expressed as elemental iron)",
"      </b>",
"     </caption>",
"     <col align=\"left\" width=\"150\">",
"     </col>",
"     <col align=\"center\" width=\"100\">",
"     </col>",
"     <thead valign=\"middle\">",
"      <tr>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Age",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         RDA",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         (mg)",
"        </p>",
"       </th>",
"      </tr>",
"     </thead>",
"     <tbody valign=\"middle\">",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         1 to &lt;5 months",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         5",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         5 months to 10 years",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         10",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\" colspan=\"2\">",
"        <p style=\"text-indent:0em;\">",
"         <b>",
"          Male",
"         </b>",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;margin-left:2em;\">",
"         11-18 years",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         12",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;margin-left:2em;\">",
"         &gt;18 years",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         10",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\" colspan=\"2\">",
"        <p style=\"text-indent:0em;\">",
"         <b>",
"          Female",
"         </b>",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;margin-left:2em;\">",
"         11-50 years",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         15",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;margin-left:2em;\">",
"         &gt;50 years",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         10",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     <b>",
"      Treatment and prevention of iron deficiency:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Infants and Children:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Severe iron deficiency anemia: 4-6 mg elemental iron/kg/day in 3 divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Mild to moderate iron deficiency anemia: 3 mg elemental iron/kg/day in 1-2 divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Prophylaxis: 1-2 mg elemental iron/kg/day up to a maximum of 15 mg elemental iron/day.",
"     <b>",
"      Note:",
"     </b>",
"     In healthy, term infants, AAP does not recommend routine additional supplementation of iron be considered until at least 4-6 months of age if breast-fed (full or partial) (Baker, 2010; Schanler, 2011)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Iron deficiency: 2-3 mg/kg/day or 60-100 mg elemental iron twice daily up to 60 mg elemental iron 4 times/day, or 50 mg elemental iron (extended release) 1-2 times/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Prophylaxis: 60-100 mg elemental iron/day",
"    </p>",
"    <table border=\"1\" frame=\"border\" rules=\"all\">",
"     <caption style=\"text-align:center;\">",
"      Elemental Iron Content of Iron Salts",
"     </caption>",
"     <col align=\"left\" width=\"220\">",
"     </col>",
"     <col align=\"center\" width=\"140\">",
"     </col>",
"     <col align=\"center\" width=\"140\">",
"     </col>",
"     <thead valign=\"middle\">",
"      <tr>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Iron Salt",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Elemental Iron Content",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         (% of salt form)",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Approximate",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         Equivalent Doses",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         (mg of iron salt)",
"        </p>",
"       </th>",
"      </tr>",
"     </thead>",
"     <tbody valign=\"middle\">",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Ferrous fumarate",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         33",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         197",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Ferrous gluconate",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         11.6",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         560",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Ferrous sulfate",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         20",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         324",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Ferrous sulfate, exsiccated",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         30",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         217",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F170889\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elixir, oral: 220 mg/5 mL (473 mL, 480 mL) [elemental iron 44 mg/5 mL]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Liquid, oral: 300 mg/5 mL (5 mL) [elemental iron ~60 mg/5 mL]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Liquid, oral [drops]: 75 mg/mL (50 mL) [elemental iron 15 mg/mL]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Fer-In-Sol&reg;: 75 mg/mL (50 mL) [gluten free; contains ethanol 0.2%, sodium bisulfite; elemental iron 15 mg/mL]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Fer-iron: 75 mg/mL (50 mL) [contains ethanol 0.2%, sodium bisulfite; lemon flavor; elemental iron 15 mg/mL]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Suspension, oral [drops]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     MyKidz Iron 10&trade;: 75 mg/1.5 mL (118 mL) [dye free, ethanol free; contains propylene glycol, sodium 12 mg/1.5 mL; strawberry-banana flavor; elemental iron 15 mg/1.5 mL]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 324 mg [elemental iron 65 mg], 325 mg [elemental iron 65 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral [exsiccated]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Feosol&reg;: 200 mg [elemental iron 65 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, enteric coated, oral: 324 mg [elemental iron 65 mg], 325 mg [elemental iron 65 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, extended release, oral: 140 mg [elemental iron 45 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, slow release, oral: 160 mg [elemental iron 50 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Slow FE&reg;: 142 mg [elemental iron 45 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Slow Release: 140 mg [elemental iron 45 mg]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F170874\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1014067\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: Do not chew or crush sustained release preparations; administer with water or juice between meals for maximum absorption; may administer with food if GI upset occurs; do not administer with milk or milk products",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1014036\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Prevention and treatment of iron deficiency anemias; supplemental therapy for patients receiving epoetin alfa",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F170955\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Feosol&reg; may be confused with Fer-In-Sol&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Fer-In-Sol&reg; may be confused with Feosol&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Slow FE&reg; may be confused with Slow-K&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Administration issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Multiple concentrations of liquid iron preparations exist. Fer-In-Sol&reg; drops (manufactured by Mead Johnson) and a limited number of generic products are available at a concentration of 15 mg/mL. However, a suspension product, MyKidz Iron 10&trade; drops, is available at a concentration of 15 mg/1.5 mL. Check concentration closely prior to dispensing. Prescriptions written in milliliters (mL) should be clarified.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F170953\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Constipation, dark stools, diarrhea, epigastric pain, GI irritation, heartburn, nausea, stomach cramping, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Discoloration of urine",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Liquid preparations may temporarily stain the teeth",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Contact irritation",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1014038\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to iron salts or any component; hemochromatosis, hemolytic anemia",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F5263086\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Avoid using for longer than 6 months, except in patients with conditions that require prolonged therapy; avoid in patients with peptic ulcer, enteritis, or ulcerative colitis; avoid in patients receiving frequent blood transfusions. Severe iron toxicity may occur in overdose, particularly when ingested by children; iron is a leading cause of fatal poisoning in children; store out of children's reach and in child-resistant containers. Liquid preparations may temporarily stain the teeth.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1014039\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Avoid use in premature infants until the vitamin E stores, deficient at birth, are replenished; some products contain sulfites which may cause allergic reactions in susceptible individuals",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299324\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F170883\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antacids: May decrease the absorption of Iron Salts.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bisphosphonate Derivatives: Iron Salts may decrease the serum concentration of Bisphosphonate Derivatives.  Management: Avoid administration of oral iron supplements within: 2 hours before or after tiludronate/clodronate/etidronate; 60 minutes after oral ibandronate; or 30 minutes after alendronate/risedronate.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Pamidronate; Zoledronic Acid.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cefdinir: Iron Salts may decrease the serum concentration of Cefdinir. Red-appearing, non-bloody stools may also develop due to the formation of an insoluble iron-cefdinir complex.  Management: Avoid concurrent cefdinir and oral iron when possible.  Separating doses by several hours may minimize interaction.  Iron-containing infant formulas do not appear to interact with cefdinir.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferiprone: Iron Salts may decrease the serum concentration of Deferiprone.  Management: Separate administration of deferiprone and oral medications or supplements that contain polyvalent cations by at least 4 hours.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dimercaprol: May enhance the nephrotoxic effect of Iron Salts.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eltrombopag: Iron Salts may decrease the serum concentration of Eltrombopag.  Management: Separate administration of eltrombopag and any orally administered polyvalent cation (e.g., iron-containing products) by at least 4 hours.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     H2-Antagonists: May decrease the absorption of Iron Salts.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Levodopa: Iron Salts may decrease the serum concentration of Levodopa. Only applies to oral iron preparations.  Management: Consider separating doses of the agents by 2 or more hours to minimize the effects of this interaction. Monitor for decreased therapeutic effects of levodopa during concomitant therapy, particularly if doses cannot be separated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Levothyroxine: Iron Salts may decrease the serum concentration of Levothyroxine.  Management: Separate oral administration of iron salts and levothyroxine by at least 4 hours.  Separation of doses is not required with parenterally administered iron salts or levothyroxine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methyldopa: Iron Salts may decrease the serum concentration of Methyldopa.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pancrelipase: May decrease the absorption of Iron Salts.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     PenicillAMINE: Iron Salts may decrease the absorption of PenicillAMINE. Only oral iron salts are a concern.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphate Supplements: Iron Salts may decrease the absorption of Phosphate Supplements.  Management: Administer oral phosphate supplements at least 1 hour before, or 2 hours after, oral iron salt administration.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Potassium Phosphate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Proton Pump Inhibitors: May decrease the absorption of Iron Salts.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Quinolone Antibiotics: Iron Salts may decrease the absorption of Quinolone Antibiotics. Of concern only with oral administration of both agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tetracycline Derivatives: Iron Salts may decrease the absorption of Tetracycline Derivatives. Only a concern with orally administered products.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trientine: Iron Salts may decrease the serum concentration of Trientine. Trientine may decrease the serum concentration of Iron Salts.  Management: Trientine manufacturer recommends avoiding concurrent administration with oral iron salts due to the risk for impaired GI absorption of both trientine and the iron salt. Short courses of iron may be used however separate administration by at least 2 hours",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F1014052\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Milk, cereals, dietary fiber, tea, coffee, or eggs decrease absorption of iron.",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F6789293\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     It is recommended that pregnant women meet the dietary requirements of iron with diet and/or supplements in order to prevent adverse events associated with iron deficiency anemia in pregnancy. Treatment of iron deficiency anemia in pregnant women is the same as in nonpregnant women and in most cases, oral iron preparations may be used. Except in severe cases of maternal anemia, the fetus achieves normal iron stores regardless of maternal concentrations.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1014068\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Serum iron, total iron binding capacity, reticulocyte count, hemoglobin, ferritin",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F1014056\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Serum iron:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Newborns: 110-270 mcg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Infants: 30-70 mcg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children: 55-120 mcg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: Male: 75-175 mcg/dL; Female: 65-165 mcg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Total iron binding capacity:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Newborns: 59-175 mcg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Infants: 100-400 mcg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children and Adults: 230-430 mcg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Transferrin: 204-360 mg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Percent transferrin saturation: 20% to 50%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Iron levels &gt;300 mcg/dL may be considered toxic; should be treated as an overdosage",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ferritin: 13-300 ng/mL",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1014055\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Iron is released from the plasma and eventually replenishes the depleted iron stores in the bone marrow where it is incorporated into hemoglobin",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F5262859\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Onset of action: Hematologic response to either oral or parenteral iron salts is essentially the same; red blood cells form and color changes within 3-10 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Maximum effect: Peak reticulocytosis occurs in 5-10 days, and hemoglobin values increase within 2-4 weeks",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1014057\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Absorption: Oral: Iron is absorbed in the duodenum and upper jejunum; in persons with normal iron stores 10% of an oral dose is absorbed, this is increased to 20% to 30% in persons with inadequate iron stores; food and achlorhydria will decrease absorption",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Elimination: Iron is largely bound to serum transferrin and excreted in the urine, sweat, sloughing of intestinal mucosa, and by menses",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1014072\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?5/22/5477?source=see_link\">",
"      see \"Ferrous sulfate: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May color the stools and urine black; liquid preparations may temporarily stain the teeth; do not take within 2 hours of tetracyclines or fluoroquinolones; do not take with milk or antacids; keep out of reach of children",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F5262860\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     When treating iron deficiency anemias, treat for 3-4 months after hemoglobin/hematocrit return to normal in order to replenish total body stores; elemental iron dosages as high as 15 mg/kg/day have been used to supplement neonates receiving concomitant epoetin alpha in the treatment of anemia of prematurity",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Baker RD, Greer FR, and Committee on Nutrition American Academy of Pediatrics, \"Diagnosis and Prevention of Iron Deficiency and Iron-Deficiency Anemia in Infants and Young Children (0-3 Years of Age),\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2010, 126(5):1040-50.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/62/15334/abstract-text/20923825/pubmed\" id=\"20923825\" target=\"_blank\">",
"        20923825",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Schanler RJ, Feldman-Winter L, Landers S, et al, \"Concerns With Early Universal Iron Supplementation of Breastfeeding Infants,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2011, 127(4):e1097.",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13056 Version 41.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-91.202.164.29-7B7E1375F2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_62_15334=[""].join("\n");
var outline_f14_62_15334=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170907\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170908\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1014035\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11442532\">",
"      Dosing: Neonatal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1014062\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170889\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170874\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1014067\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1014036\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170955\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170953\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1014038\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5263086\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1014039\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299324\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170883\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1014052\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6789293\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1014068\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1014056\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1014055\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5262859\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1014057\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1014072\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5262860\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13056\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13056|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?36/11/37046?source=related_link\">",
"      Ferrous sulfate: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?5/22/5477?source=related_link\">",
"      Ferrous sulfate: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_62_15335="Gastric MALToma B cell stain";
var content_f14_62_15335=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F59651&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F59651&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 567px\">",
"   <div class=\"ttl\">",
"    Extranodal marginal zone lymphoma of the stomach (gastric MALToma)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 547px; height: 180px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Low-grade B cell lymphoma of the MALT-type. Left panel: Infiltrating lymphoma cells with loss of glands and a lymphoepithelial lesion. Right panel: Staining with the monoclonal B cell antibody CD-20 shows that most of the infiltrating cells show B cell reactivity.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul C Schroy III, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_62_15335=[""].join("\n");
var outline_f14_62_15335=null;
var title_f14_62_15336="Gastric MALT lymphoma Light";
var content_f14_62_15336=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F61021&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F61021&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Gastric MALT lymphoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 369px; height: 562px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Biopsy of a gastric MALT lymphoma showing a dense cellular infiltrate showing virtually complete obliteration of the normal architecture (upper panel). At high power (lower panel) the infiltrate is composed of atypical lymphoid cells that are infiltrating and partially destroying the glands (arrows), referred to as \"lymphoepithelial lesions\". Immunohistochemical studies demonstrated that the lymphoid cells were CD20 positive and CD5 and 10 negative. This findings supports the diagnosis of mucosa-associated lymphoma (MALT). The other major consideration in the differential diagnosis is poorly differentiated carcinoma, which would be negative with the CD makers but positive with stains for cytokeratins. Special stainings revealed the presence of Helicobacter pylori.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Heather Crowley, MD and Donald Antonioli, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_62_15336=[""].join("\n");
var outline_f14_62_15336=null;
var title_f14_62_15337="Button and cylindrical battery ingestion";
var content_f14_62_15337=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Button and cylindrical battery ingestion",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/62/15337/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/62/15337/contributors\">",
"     Kelly Sinclair, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/62/15337/contributors\">",
"     Ivor D Hill, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/62/15337/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/62/15337/contributors\">",
"     Michele Burns Ewald, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/62/15337/contributors\">",
"     George D Ferry, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/62/15337/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/62/15337/contributors\">",
"     James F Wiley, II, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?14/62/15337/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 27, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Button (or disc) batteries power a multitude of products, such as remote control devices, calculators, watches, hearing aids, handheld games, clocks, and key chains. Ingested button batteries have strong potential for corrosive injury to the gastrointestinal tract with major complications, including esophageal burns, fistula, or perforation. Most button battery ingestions are witnessed, and up to 80 percent of patients are asymptomatic at the time of presentation. The management of button battery ingestions, including radiographic localization and removal, depends upon the location of the battery and the age of the patient. Neither battery size nor the presence of symptoms can be used to reliably predict esophageal location in children.",
"   </p>",
"   <p>",
"    The evaluation and management of button battery ingestion will be presented here. The management of button batteries in the ear or nose and esophageal foreign bodies, other than button batteries, is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/53/28504?source=see_link\">",
"     \"Diagnosis and management of foreign bodies of the outer ear\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/21/17752?source=see_link\">",
"     \"Diagnosis and management of intranasal foreign bodies\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/22/1386?source=see_link\">",
"     \"Foreign bodies of the esophagus and gastrointestinal tract in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/54/21353?source=see_link\">",
"     \"Ingested foreign bodies and food impactions in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The National Battery Ingestion Hotline (NBIH) was created in 1982 and collects data, provides consultation, and promulgates recommendations for battery ingestions [",
"    <a class=\"abstract\" href=\"UTD.htm?14/62/15337/abstract/1\">",
"     1",
"    </a>",
"    ]. Up to 15 battery ingestion cases per one million people occur each year in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?14/62/15337/abstract/2\">",
"     2",
"    </a>",
"    ]. The incidence has increased with expanded use of button batteries in household and recreational products [",
"    <a class=\"abstract\" href=\"UTD.htm?14/62/15337/abstract/1-8\">",
"     1-8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    From 2007 to 2009, serious sequelae occurred in 2.7 percent of all button battery ingestions reported to the National Poison Data System which compiles all calls to United States regional poison control centers [",
"    <a class=\"abstract\" href=\"UTD.htm?14/62/15337/abstract/2\">",
"     2",
"    </a>",
"    ]. Ingestion of large diameter (&ge;20 mm) lithium cell batteries was strongly associated with major outcomes (eg, esophageal burn, perforation, or fistula) and death.",
"   </p>",
"   <p>",
"    Battery ingestion has been described in several retrospective case series [",
"    <a class=\"abstract\" href=\"UTD.htm?14/62/15337/abstract/1,3-5,9\">",
"     1,3-5,9",
"    </a>",
"    ]. The largest series, from the NBIH, describes 8648 battery ingestions, 94 percent of which involved button batteries and 6 percent of which involved cylindrical batteries (eg, AA, AAA, C, N) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/62/15337/abstract/9\">",
"     9",
"    </a>",
"    ]. In this series of battery ingestions:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The majority of ingestions occurred in children younger than six years of age, with the peak frequency between one and two years of age.",
"     </li>",
"     <li>",
"      Among children, over half of the batteries were ingested immediately after removal from a product.",
"     </li>",
"     <li>",
"      Ingested batteries were obtained from a variety of devices including (in decreasing order of frequency) hearing aids, games and toys, watches, calculators, lighting devices (eg, flashlights,",
"      <span class=\"nowrap\">",
"       light/laser",
"      </span>",
"      pointer, penlight), and remote control devices (eg, television, garage door, key fob).",
"     </li>",
"     <li>",
"      By 2008, 18 percent of ingested batteries were &ge;20 mm, and most of these large diameter batteries were lithium cells. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Battery description'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Patients with hearing aid battery ingestions were the user of the hearing aid in a large majority of cases.",
"     </li>",
"     <li>",
"      In a significant number of ingestions, the hearing aid battery was mistaken for a pill. A common scenario involved storage of hearing aid batteries near medications. In some instances, the patient swallowed the battery and then realized their mistake when they tried to put their pill into the hearing aid and found it did not fit.",
"     </li>",
"     <li>",
"      Other reasons for ingestion included placement on the tongue to \"test\" the battery, holding the battery in the mouth, and suicidal intent.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These findings suggest that parents and users of hearing aids should be made aware of the danger of button battery ingestion. In addition, measures by the manufacturer to secure the battery compartment of devices using button batteries could prevent over half of pediatric button battery ingestions. (See",
"    <a class=\"local\" href=\"#H23\">",
"     'Prevention'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     BATTERY DESCRIPTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Between 30 and 60 percent of each battery contains inert components [",
"    <a class=\"abstract\" href=\"UTD.htm?14/62/15337/abstract/4\">",
"     4",
"    </a>",
"    ]. The active portion of the battery consists of a negative terminal and a positive terminal (",
"    <a class=\"graphic graphic_figure graphicRef54101 \" href=\"UTD.htm?15/5/15440\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/62/15337/abstract/10\">",
"     10",
"    </a>",
"    ]. The negative terminal of the battery is typically made of zinc or lithium, and the positive terminal of one of the following substances [",
"    <a class=\"abstract\" href=\"UTD.htm?14/62/15337/abstract/2,4\">",
"     2,4",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Oxygen (zinc-air cells,1.5 volts)",
"     </li>",
"     <li>",
"      Silver oxide (1.5 volts)",
"     </li>",
"     <li>",
"      Mercuric oxide (1.5 volts)",
"     </li>",
"     <li>",
"      Lithium&nbsp;manganese (3 volts)",
"     </li>",
"     <li>",
"      Manganese dioxide (1.5 volts)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The negative terminal is the narrow portion of the battery where the electric current flows into the tissue and usually creates the most damage.",
"   </p>",
"   <p>",
"    The negative and positive terminals are typically separated by a disc that is embedded with potassium hydroxide, sodium hydroxide, or an organic solution with varying concentrations [",
"    <a class=\"abstract\" href=\"UTD.htm?14/62/15337/abstract/11\">",
"     11",
"    </a>",
"    ]. The terminals and salt solution are encased in steel",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    nickel (",
"    <a class=\"graphic graphic_figure graphicRef54101 \" href=\"UTD.htm?15/5/15440\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     BATTERY IDENTIFICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Button batteries range in diameter from 6 to 25 mm, a range that closely approximates that of pills. Most of the items powered by button batteries use batteries that are less than 15 mm in diameter [",
"    <a class=\"abstract\" href=\"UTD.htm?14/62/15337/abstract/1\">",
"     1",
"    </a>",
"    ]. Batteries that are greater than 12 mm in diameter are most likely to become lodged in the esophagus, especially in young children.",
"   </p>",
"   <p>",
"    The chemical content, diameter, and height of the battery can be determined from the imprinted code found on the battery case as determined by the International Electrotechnical Commission [",
"    <a class=\"abstract\" href=\"UTD.htm?14/62/15337/abstract/12\">",
"     12",
"    </a>",
"    ]. The first letter gives the chemical identification of the positive terminal as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      L: Manganese dioxide",
"     </li>",
"     <li>",
"      S: Silver oxide",
"     </li>",
"     <li>",
"      P: Oxygen",
"     </li>",
"     <li>",
"      C: Manganese dioxide",
"     </li>",
"     <li>",
"      B: Carbon monofluoride",
"     </li>",
"     <li>",
"      G: Copper oxide",
"     </li>",
"     <li>",
"      LR (or AG): Alkaline",
"     </li>",
"     <li>",
"      SR: Silver oxide",
"     </li>",
"     <li>",
"      CR:",
"      <span class=\"nowrap\">",
"       Lithium/manganese",
"      </span>",
"      dioxide",
"     </li>",
"     <li>",
"      BR: Lithium carbon monofluoride",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A battery with a three number code has the diameter given by the first number (eg, SR516 is 5 mm in diameter).",
"   </p>",
"   <p>",
"    A battery with a four number code has the diameter given by the first two numbers (eg, CR2032 is 20 mm in diameter).",
"   </p>",
"   <p>",
"    The last two numbers give the battery height in tenths of millimeters (eg, CR2032 is 3.2 mm in height).",
"   </p>",
"   <p>",
"    The package code also corresponds to the battery diameter in mm. For example, a battery with a package code of 23 has a diameter of 23 mm.",
"   </p>",
"   <p>",
"    The type of device from which the battery was removed or for which it was intended may also help in identification as indicated below [",
"    <a class=\"abstract\" href=\"UTD.htm?14/62/15337/abstract/10\">",
"     10",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Calculator &ndash; HgO, AgO",
"     </li>",
"     <li>",
"      Camera &ndash; HgO, MnO2",
"     </li>",
"     <li>",
"      Computer game &ndash; HgO, AgO",
"     </li>",
"     <li>",
"      Hearing aid &ndash; HgO, AgO, zinc-air",
"     </li>",
"     <li>",
"      Watch &ndash; AgO, HgO, MnO2, lithium",
"     </li>",
"     <li>",
"      Remote control &ndash; Lithium",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mechanisms of injury from battery ingestion include electrical discharge, pressure necrosis, and leakage of battery contents [",
"    <a class=\"abstract\" href=\"UTD.htm?14/62/15337/abstract/2,4,5\">",
"     2,4,5",
"    </a>",
"    ], each of which contribute to corrosive damage when the battery is in contact with a mucosal surface for a sufficient period of time. However, electrical discharge appears to be the most prominent mechanism in most clinically significant cases.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Electrical discharge",
"    </span>",
"    &nbsp;&mdash;&nbsp;The flow of electric current from the battery through the surrounding tissue occurs near the negative pole and can cause local hydrolysis, hydroxide accumulation, and corrosive tissue injury [",
"    <a class=\"abstract\" href=\"UTD.htm?14/62/15337/abstract/3,13-16\">",
"     3,13-16",
"    </a>",
"    ]. The corrosive injury caused by electrical discharge cannot be differentiated from that caused by leakage of battery contents. However, this mechanism appears of primary importance for the following reasons:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In an in vitro study, after less than one minute, the electric discharge from a battery generated enough sodium hydroxide at and near the anode to raise the pH to 11 [",
"      <a class=\"abstract\" href=\"UTD.htm?14/62/15337/abstract/13\">",
"       13",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Several case reports describe increased severity of mucosal injury near the negative pole of batteries removed from the esophagus [",
"      <a class=\"abstract\" href=\"UTD.htm?14/62/15337/abstract/13\">",
"       13",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Major complications (eg, esophageal burns, fistula, or perforation) and deaths are associated with lithium batteries which contain higher voltage (3 volts) and capacitance than most other button batteries [",
"      <a class=\"abstract\" href=\"UTD.htm?14/62/15337/abstract/2\">",
"       2",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Battery description'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Among patients who ingested large (&ge;20 mm in diameter) button batteries, clinically significant esophageal injury was significantly associated with new batteries [",
"      <a class=\"abstract\" href=\"UTD.htm?14/62/15337/abstract/2\">",
"       2",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Significant esophageal mucosal injury has been documented in patients with intact batteries lodged for less than two hours, an insufficient amount of time for pressure necrosis [",
"      <a class=\"abstract\" href=\"UTD.htm?14/62/15337/abstract/2\">",
"       2",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Discharged batteries still retain enough voltage and storage capability to generate an external current. Thus, ingestion of \"dead\" button batteries is still a major concern.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Leakage of contents",
"    </span>",
"    &nbsp;&mdash;&nbsp;In an acidic environment such as the stomach, the seal or crimp of the battery may erode, potentially releasing chemical contents, including sodium or potassium hydroxide [",
"    <a class=\"abstract\" href=\"UTD.htm?14/62/15337/abstract/17-19\">",
"     17-19",
"    </a>",
"    ]. In vitro experiments and examination of ingested batteries after passage through the gastrointestinal (GI) tract provide information about the likelihood of dissolution of the battery seal [",
"    <a class=\"abstract\" href=\"UTD.htm?14/62/15337/abstract/1,19\">",
"     1,19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the large series of cases from the NBIH, 1809 batteries were available for examination after transit through the GI tract [",
"      <a class=\"abstract\" href=\"UTD.htm?14/62/15337/abstract/2\">",
"       2",
"      </a>",
"      ]. Two percent of the batteries fragmented within the GI tract and 13 percent had severe crimp dissolution or extensive perforations. Severe outcomes were significantly more likely in patients with severe crimp dissolution or battery fragmentation (4 versus 1 percent).",
"     </li>",
"     <li>",
"      In an in vitro experiment, button batteries were placed into a 0.1 N hydrochloric acid solution to mimic the pH of the stomach [",
"      <a class=\"abstract\" href=\"UTD.htm?14/62/15337/abstract/19\">",
"       19",
"      </a>",
"      ]. The percent erosion of the crimp seal after 24 hours was directly related to the amount of charge remaining in the battery, with complete crimp dissolution in fully charged cells, 50 to 60 percent dissolution in 50 percent discharged cells, 10 to 20 percent dissolution in 75 percent discharged cells, and only minor pitting in the fully discharged cells [",
"      <a class=\"abstract\" href=\"UTD.htm?14/62/15337/abstract/19\">",
"       19",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Alkaline solutions",
"    </span>",
"    &nbsp;&mdash;&nbsp;As the alkaline solutions (potassium",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    sodium hydroxide) react with the exposed proteins on the mucosal surface of the GI tract, they may cause liquefaction necrosis and saponification of lipid membranes [",
"    <a class=\"abstract\" href=\"UTD.htm?14/62/15337/abstract/20\">",
"     20",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/23/4473?source=see_link\">",
"     \"Caustic esophageal injury in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The dissolution process is slowed somewhat when the battery enters the intestines, where the pH is higher than in the stomach [",
"    <a class=\"abstract\" href=\"UTD.htm?14/62/15337/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Heavy metals",
"    </span>",
"    &nbsp;&mdash;&nbsp;Absorption of heavy metals from broken or fragmented batteries is another potential mechanism of injury. However, cases of heavy metal poisoning from disc battery ingestion are quite rare. In one case, a five-year-old boy's serum lithium concentration peaked at 0.7",
"    <span class=\"nowrap\">",
"     mEq/L",
"    </span>",
"    after swallowing a button battery [",
"    <a class=\"abstract\" href=\"UTD.htm?14/62/15337/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Mercury batteries are the most concerning in this regard because they are the most likely to fragment [",
"    <a class=\"abstract\" href=\"UTD.htm?14/62/15337/abstract/1\">",
"     1",
"    </a>",
"    ], and because of the potential severity of mercury poisoning. However, mercury toxicity from battery ingestions is extremely rare. There are several case reports describing elevated serum or urine levels of mercury after battery ingestion with radiologic evidence of battery fragmentation and radiopaque droplets in the intestines [",
"    <a class=\"abstract\" href=\"UTD.htm?14/62/15337/abstract/1,3,4,17,22-25\">",
"     1,3,4,17,22-25",
"    </a>",
"    ]. However, none of the involved patients had clinical signs or symptoms of mercury toxicity. In the one possible case where symptoms of mercury poisoning (malaise and lethargy) were present, mercury levels were not obtained [",
"    <a class=\"abstract\" href=\"UTD.htm?14/62/15337/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The absence of symptomatic cases of mercury poisoning among battery ingestion victims is thought to be related to the conversion of mercuric oxide to the less easily absorbed elemental mercury in the presence of soluble iron (released from the corrosion of the steel casing), according to the following reactions [",
"    <a class=\"abstract\" href=\"UTD.htm?14/62/15337/abstract/27\">",
"     27",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    HgO + 2HCl &ndash;&gt; HgCl2 + H2O",
"   </p>",
"   <p>",
"    &nbsp;HgCl2 + Fe &ndash;&gt; FeCl2 + Hg",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Pressure necrosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;When an ingested foreign body, such as a button battery, lodges at a single site, it can place pressure on the surrounding tissue and cause irritation, inflammation, and ischemia. This series of events may lead to tissue necrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?14/62/15337/abstract/5,20,28\">",
"     5,20,28",
"    </a>",
"    ]. The magnitude of the contribution of pressure necrosis to the overall mucosal damage in patients after button battery ingestions is less certain [",
"    <a class=\"abstract\" href=\"UTD.htm?14/62/15337/abstract/3,4\">",
"     3,4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;In most instances, battery ingestions are witnessed or the child tells the caregiver about the ingestion. The clinician should obtain the following information:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Battery type &ndash; The battery type may be known by the patient or caregiver, available from the code on an identical battery, or determined based on descriptions of the battery or the device it operates [",
"      <a class=\"abstract\" href=\"UTD.htm?14/62/15337/abstract/29\">",
"       29",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Battery identification'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      Most large diameter (&ge;20 mm) batteries are lithium cells and are associated with the most severe sequelae, including death [",
"      <a class=\"abstract\" href=\"UTD.htm?14/62/15337/abstract/2\">",
"       2",
"      </a>",
"      ]. For comparison, a dime is 18 mm, a nickel 21 mm, and a quarter 24 mm in diameter [",
"      <a class=\"abstract\" href=\"UTD.htm?14/62/15337/abstract/2,22\">",
"       2,22",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Complications'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Battery charge state &ndash; The charge state of the battery is important because new batteries are associated with a greater potential for tissue damage if they are &ge;20 mm in diameter [",
"      <a class=\"abstract\" href=\"UTD.htm?14/62/15337/abstract/2\">",
"       2",
"      </a>",
"      ]. However, \"dead\" batteries still have significant potential for tissue damage.",
"     </li>",
"     <li>",
"      Time of ingestion &ndash; The time elapsed since ingestion can indicate the severity of damage, particularly when it exceeds two to four hours.",
"     </li>",
"     <li>",
"      Number of batteries ingested &ndash; Ingestion of multiple button batteries was associated with clinically significant outcomes [",
"      <a class=\"abstract\" href=\"UTD.htm?14/62/15337/abstract/2\">",
"       2",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Magnet coingestion &ndash; Although rare, ingestion of a button battery and a magnet may lead to bowel necrosis and perforation should the intestinal wall be trapped between the battery and the magnet [",
"      <a class=\"abstract\" href=\"UTD.htm?14/62/15337/abstract/2,30\">",
"       2,30",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Signs and symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients are asymptomatic although one or more of the following symptoms may be present [",
"    <a class=\"abstract\" href=\"UTD.htm?14/62/15337/abstract/1-4,10\">",
"     1-4,10",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Chest pain",
"     </li>",
"     <li>",
"      Cough",
"     </li>",
"     <li>",
"      Anorexia",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       Nausea/vomiting",
"      </span>",
"     </li>",
"     <li>",
"      Hematemesis",
"     </li>",
"     <li>",
"      Diarrhea",
"     </li>",
"     <li>",
"      Epigastric pain",
"     </li>",
"     <li>",
"      Abdominal pain",
"     </li>",
"     <li>",
"      Fever",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Many of these symptoms are caused by the battery's lodging within the esophagus, where it can cause corrosive tissue damage. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/22/1386?source=see_link\">",
"     \"Foreign bodies of the esophagus and gastrointestinal tract in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Additional clinical features include dysphagia, drooling, and black flecks in the saliva [",
"    <a class=\"abstract\" href=\"UTD.htm?14/62/15337/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The clinician should also maintain a high level of suspicion for an esophageal button battery or other foreign body, despite a negative history of ingestion, in young children who are refusing oral intake. In a case series of 13 deaths after button battery ingestion, misdiagnosis occurred in seven patients because of a lack of ingestion history combined with nonspecific presenting symptoms such as fever, vomiting, lethargy, poor appetite, irritability, cough, wheezing,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    dehydration [",
"    <a class=\"abstract\" href=\"UTD.htm?14/62/15337/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The National Battery Ingestion Hotline (NBIH) (202-625-3333, TDD 202-362-8563) or one of the regional Poison Control Centers in the US (1-800-222-1222) is available to provide guidance for the management of patients with button battery ingestions. If available, the clinician should try to determine the battery identification code, which is typically located on the package or on a matching battery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Button batteries",
"    </span>",
"    &nbsp;&mdash;&nbsp;As with all acute ingestions, stabilization of the cardiorespiratory status is the first priority. However, since most patients with button battery ingestion are asymptomatic or present in stable condition, localization of the battery is typically the first step.",
"   </p>",
"   <p>",
"    A guideline for the evaluation and management of button battery ingestions is available at the National Battery Ingestion Hotline website [",
"    <a class=\"abstract\" href=\"UTD.htm?14/62/15337/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Radiographic localization",
"    </span>",
"    &nbsp;&mdash;&nbsp;Batteries should be localized with prompt anteroposterior (AP) and lateral radiographs of the nasopharynx, chest, and abdomen in all children &le;12 years of age, in all patients who have ingested a button battery that is &ge;12 mm in diameter, or in patients for whom the diameter of the battery is not known [",
"    <a class=\"abstract\" href=\"UTD.htm?14/62/15337/abstract/2,31\">",
"     2,31",
"    </a>",
"    ]. Because as many as 8.5 percent of cases involve ingestion of multiple items, the radiographs should cover the area from the nasopharynx to the anus [",
"    <a class=\"abstract\" href=\"UTD.htm?14/62/15337/abstract/15,32\">",
"     15,32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In asymptomatic, healthy patients over 12 years of age with confirmed ingestion of a solitary, small (&le;12 mm in diameter) battery and without coingestion of a magnet, radiography may be deferred [",
"    <a class=\"abstract\" href=\"UTD.htm?14/62/15337/abstract/2,31\">",
"     2,31",
"    </a>",
"    ]. These patients may undergo observation for battery passage at home without initial radiographs as long as the patient or caregiver is reliable and able to promptly seek treatment should symptoms develop. Radiographic localization is warranted if battery passage is not confirmed in 10 to 14 days.",
"   </p>",
"   <p>",
"    As described above, patients with button battery ingestions usually present with a chief complaint of button battery ingestion. When the ingestion is an incidental finding on plain radiograph, it may be difficult to differentiate between a button battery and a coin. This distinction is most important when the foreign body is in the esophagus, since batteries require removal whereas coins may or may not. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/22/1386?source=see_link\">",
"     \"Foreign bodies of the esophagus and gastrointestinal tract in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Enlargement of the radiograph may help to demonstrate the characteristic features of button batteries versus coins:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Button batteries have a bilaminar structure, making them appear as a double-ring or halo on plain radiographs. The double-ring shadow helps to differentiate battery from coin ingestions (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef62847 \" href=\"UTD.htm?25/39/26239\">",
"       image 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      On lateral view of the foreign body, the button battery has a step-off at the separation between the anode and cathode (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef77690 \" href=\"UTD.htm?38/21/39263\">",
"       image 2",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?14/62/15337/abstract/33\">",
"       33",
"      </a>",
"      ]. In contrast, the coin has a sharp, crisp edge (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef77690 \" href=\"UTD.htm?38/21/39263\">",
"       image 2",
"      </a>",
"      ). Misidentifying the foreign body as a coin when it is actually a battery can have significant adverse consequences. As an example, an 11-month-old infant incurred bilateral vocal cord paralysis when a button battery was misread as a coin on x-ray; she remained intubated for six days [",
"      <a class=\"abstract\" href=\"UTD.htm?14/62/15337/abstract/34\">",
"       34",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Esophageal position",
"    </span>",
"    &nbsp;&mdash;&nbsp;Esophageal foreign bodies tend to lodge in areas of physiologic narrowing, such as the cricopharyngeus muscle (upper esophageal sphincter), the level of the aortic arch, and the lower esophageal sphincter (",
"    <a class=\"graphic graphic_figure graphicRef52252 \" href=\"UTD.htm?20/11/20659\">",
"     figure 2",
"    </a>",
"    ). Objects greater than 50 mm in length or 20 mm in diameter are less likely to pass into the stomach [",
"    <a class=\"abstract\" href=\"UTD.htm?14/62/15337/abstract/35\">",
"     35",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/22/1386?source=see_link\">",
"     \"Foreign bodies of the esophagus and gastrointestinal tract in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Button batteries that are lodged in the esophagus should be",
"    <strong>",
"     emergently removed",
"    </strong>",
"    with direct endoscopic visualization. Airway compromise from esophageal edema has been reported as early as three hours post-ingestion, and esophageal injury has occurred in patients with a battery lodged for less than two hours [",
"    <a class=\"abstract\" href=\"UTD.htm?14/62/15337/abstract/3,14,22\">",
"     3,14,22",
"    </a>",
"    ]. General anesthesia with endotracheal intubation usually is recommended to protect the airway during performance of this procedure. Reported success rates for esophageal removal are approximately 90 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?14/62/15337/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The severity of esophageal damage after button battery ingestion depends upon the length of time that the battery is lodged in place, the amount of electrical charge remaining, and the size of the battery [",
"    <a class=\"abstract\" href=\"UTD.htm?14/62/15337/abstract/14,32,36\">",
"     14,32,36",
"    </a>",
"    ]. Damage to the esophagus may be seen as early as two hours after ingestion, with more severe damage after 8 to 12 hours [",
"    <a class=\"abstract\" href=\"UTD.htm?14/62/15337/abstract/4,14,17\">",
"     4,14,17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In animal models, full-thickness esophageal injury occurs within four hours of ingestion [",
"    <a class=\"abstract\" href=\"UTD.htm?14/62/15337/abstract/32\">",
"     32",
"    </a>",
"    ]. As the duration of impaction increases, the mucosa becomes edematous and the battery adheres tightly to the mucosa. If the battery remains in place, ulceration and perforation can occur [",
"    <a class=\"abstract\" href=\"UTD.htm?14/62/15337/abstract/15,36\">",
"     15,36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is important to observe the patient for complications after the battery is removed. Esophageal perforation and tracheoesophageal fistula (TEF) with erosion into the aorta or other arteries are rare complications, described in case reports and case series [",
"    <a class=\"abstract\" href=\"UTD.htm?14/62/15337/abstract/37-40\">",
"     37-40",
"    </a>",
"    ]. Although these injuries are not necessarily apparent at the time of endoscopy, they appear to be seen in children with moderate to severe esophageal injury at the time of battery removal. Fatal complications have been described 1 to 18 days after battery removal.",
"   </p>",
"   <p>",
"    Imaging (eg, esophagram, computed tomography [CT] of the chest) or endoscopy within a few days after battery removal has been suggested for active surveillance of such children [",
"    <a class=\"abstract\" href=\"UTD.htm?14/62/15337/abstract/38\">",
"     38",
"    </a>",
"    ]. Of these options, CT is most likely to detect esophageal perforation. Early strictures are typically seen on esophagram or endoscopy although endoscopy carries the risk of iatrogenic esophageal perforation.",
"   </p>",
"   <p>",
"    Symptoms of esophageal perforation or TEF in children with button battery ingestion include hematemesis, inability to swallow, drooling,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    respiratory distress. The management of children with upper gastrointestinal bleeding in association with a button battery ingestion depends upon the clinical setting [",
"    <a class=\"abstract\" href=\"UTD.htm?14/62/15337/abstract/38\">",
"     38",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with a low-volume sentinel bleed warrant rapid hemodynamic stabilization and emergent localization of the battery. Impacted batteries should be removed emergently in the operating room with pediatric",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      cardiothoracic surgeons present and prepared to perform thoracotomy.",
"     </li>",
"     <li>",
"      Patients with active bleeding warrant endotracheal intubation, hemodynamic stabilization, and emergent thoracotomy in the operating room. Placement of a Blakemore tube designed to tamponade esophageal sites of bleeding may be a temporizing measure if the tube and clinicians knowledgeable with its use are available.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Esophageal stenosis is a late complication of button battery ingestion (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef63376 \" href=\"UTD.htm?27/54/28515\">",
"     image 3",
"    </a>",
"    ). When it occurs, it typically does so weeks to months after endoscopic removal [",
"    <a class=\"abstract\" href=\"UTD.htm?14/62/15337/abstract/1,37\">",
"     1,37",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/23/4473?source=see_link&amp;anchor=H20530365#H20530365\">",
"     \"Caustic esophageal injury in children\", section on 'Stricture formation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Before endoscopy became a standard technique for removal of esophageal batteries, other techniques were used with some regularity. The two most common were Foley catheter removal [",
"    <a class=\"abstract\" href=\"UTD.htm?14/62/15337/abstract/4\">",
"     4",
"    </a>",
"    ] and retrieval of the battery via insertion of an orogastric tube with a magnet attached to the distal end [",
"    <a class=\"abstract\" href=\"UTD.htm?14/62/15337/abstract/41-43\">",
"     41-43",
"    </a>",
"    ]. However, such \"blind\" techniques do not permit evaluation of the esophageal mucosa surrounding the battery, and have increased risk of emesis, lodging of the battery in the esophagus, and esophageal perforation. These techniques are",
"    <strong>",
"     not",
"    </strong>",
"    recommended [",
"    <a class=\"abstract\" href=\"UTD.htm?14/62/15337/abstract/2-4,15,28,44\">",
"     2-4,15,28,44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Position distal to esophagus",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the management of patients with batteries distal to the esophagus, the NBIH suggests the following approach for follow-up radiographs and endoscopic or surgical removal [",
"    <a class=\"abstract\" href=\"UTD.htm?14/62/15337/abstract/1,2,31\">",
"     1,2,31",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There should be no initial attempt to retrieve batteries that have passed beyond the esophagus unless the patient has signs and symptoms of significant gastrointestinal injury (eg, severe pain, obstruction, hematemesis, hematochezia) or has coingested a magnet.",
"     </li>",
"     <li>",
"      If the patient has no signs of serious gastrointestinal injury or obstruction, they should be managed at home with a normal diet and activity.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Obtain follow-up radiographs:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If the patient becomes symptomatic",
"     </li>",
"     <li>",
"      Four days after ingestion in children under six years of age who have ingested a button battery with a diameter &ge;15 mm",
"     </li>",
"     <li>",
"      To prove ultimate passage of the battery if not visualized intact in the stool one to two weeks after ingestion",
"     </li>",
"     <li>",
"      Weekly to monitor progression of the battery through the GI tract if it has not been seen in the stool and is present on follow-up radiographs",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Endoscopic or surgical removal of the battery is suggested when:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The battery remains in the stomach for more than 48 hours and is unlikely to pass due to large size (eg, &ge;15 mm in diameter in a child under six years of age) [",
"      <a class=\"abstract\" href=\"UTD.htm?14/62/15337/abstract/17,45\">",
"       17,45",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The patient develops signs of gastrointestinal injury, such as hematochezia, melena, or acute abdomen.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Successful endoscopic removal of button batteries from the stomach is less likely than from the esophagus (33 to 66 percent versus 90 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/62/15337/abstract/1,4,5\">",
"     1,4,5",
"    </a>",
"    ]. In addition, there is a low risk of damage from the battery once it has cleared the esophagus, unless it becomes impacted in the gastric or intestinal mucosa [",
"    <a class=\"abstract\" href=\"UTD.htm?14/62/15337/abstract/1,17,36\">",
"     1,17,36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The induction of emesis is not recommended for batteries in the stomach because batteries are dense and unlikely to be expelled. In the NBIH series, emetics were administered to 57 patients, but successful in only four [",
"    <a class=\"abstract\" href=\"UTD.htm?14/62/15337/abstract/1\">",
"     1",
"    </a>",
"    ]. In addition, induced emesis may cause the battery to lodge in the esophagus.",
"   </p>",
"   <p>",
"    In the NBIH series, 74 percent of 4887 patients passed the battery in the stool less than 96 hours after ingestion; 11 percent took more than one week [",
"    <a class=\"abstract\" href=\"UTD.htm?14/62/15337/abstract/14\">",
"     14",
"    </a>",
"    ]. Arrested battery transit was rare. Prolonged battery transit time was more common in patients over 65 years of age.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Mercury toxicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Symptomatic mercury toxicity after button battery ingestion has not been reported and is unlikely after ingestion of a mercury containing button battery.",
"   </p>",
"   <p>",
"    However, because of the potential severity of mercury poisoning, patients with batteries that have fragmented or who demonstrate radiopaque droplets in the intestines on follow-up radiographs should have mercury levels measured and be evaluated for signs and symptoms of mercury poisoning [",
"    <a class=\"abstract\" href=\"UTD.htm?14/62/15337/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Signs and symptoms of mercury toxicity include intention tremor, ataxia, psychiatric disturbances, anorexia, weakness, hyperreflexia, and paresthesias. Mercury also can impair kidney function, leading to a nephrotic-like syndrome",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    tubular injury with tubular dysfunction. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/31/34295?source=see_link&amp;anchor=H12#H12\">",
"     \"Epidemiology and toxicity of mercury\", section on 'Nephrotoxicity'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The diagnosis of mercury poisoning is made by measuring mercury in the blood or urine [",
"    <a class=\"abstract\" href=\"UTD.htm?14/62/15337/abstract/10\">",
"     10",
"    </a>",
"    ]. Urine mercury concentrations are best for confirming exposure to elemental or inorganic mercury (eg, mercuric oxide exposure from a leaking button battery). Levels greater than 20",
"    <span class=\"nowrap\">",
"     mcg/L",
"    </span>",
"    are considered elevated; definite symptoms of toxicity are usually not evident until the urine concentration exceeds 300",
"    <span class=\"nowrap\">",
"     mcg/L.",
"    </span>",
"    Blood levels &gt;5",
"    <span class=\"nowrap\">",
"     mcg/L",
"    </span>",
"    are considered elevated, but only accurately indicate inorganic mercury exposure if they are obtained soon after mercury absorption [",
"    <a class=\"abstract\" href=\"UTD.htm?14/62/15337/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Chelation therapy is indicated for patients who have symptoms of mercury toxicity and elevated mercury levels. Such therapy should be provided in consultation with a medical toxicologist",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    regional Poison Control Center (1-800-222-1222).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Unproven therapies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Therapies that have been attempted in some children, but have unproven benefit or insufficient evidence to be recommended routinely include manipulation of pH, increasing GI motility, bowel irrigation, and repeated enemas.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Manipulating pH &ndash; Various attempts have been made to minimize injury by manipulation of pH in the environment of the battery.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Antacids and H2-antagonists have been administered in attempts to neutralize the pH of the stomach in hopes of slowing the dissolution of the battery seal [",
"      <a class=\"abstract\" href=\"UTD.htm?14/62/15337/abstract/19\">",
"       19",
"      </a>",
"      ]. Neither of these agents was successful [",
"      <a class=\"abstract\" href=\"UTD.htm?14/62/15337/abstract/19\">",
"       19",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Attempts to neutralize the alkali released from esophageal batteries also have been unsuccessful. In an in vivo study in 24 cats, boluses of normal saline, Mylanta II, orange juice, and 0.25 percent",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?41/39/42610?source=see_link\">",
"       acetic acid",
"      </a>",
"      were administered in an attempt to modulate esophageal injury [",
"      <a class=\"abstract\" href=\"UTD.htm?14/62/15337/abstract/44\">",
"       44",
"      </a>",
"      ]. Administration of these solutions did not affect gross or histologic esophageal damage when compared with controls.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Increasing motility &ndash; Attempts to increase GI motility (eg, by using",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?0/47/759?source=see_link\">",
"       metoclopramide",
"      </a>",
"      ) to speed passage of the battery through the GI tract have been tried, but they have not proven effective enough to be recommended on a regular basis [",
"      <a class=\"abstract\" href=\"UTD.htm?14/62/15337/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Cathartics &ndash; In one case report, a large volume of",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?24/38/25189?source=see_link\">",
"       polyethylene glycol",
"      </a>",
"      (PEG) oral electrolyte solution (118 g in 2 L of water) was used to flush a battery through the intestines of a child [",
"      <a class=\"abstract\" href=\"UTD.htm?14/62/15337/abstract/47\">",
"       47",
"      </a>",
"      ]. Such large volumes of PEG are not approved by the US Food and Drug Administration (FDA). Other methods of whole gut lavage",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      repeated enemas [",
"      <a class=\"abstract\" href=\"UTD.htm?14/62/15337/abstract/23\">",
"       23",
"      </a>",
"      ] have been tried with limited success [",
"      <a class=\"abstract\" href=\"UTD.htm?14/62/15337/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Cylindrical batteries",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most cylindrical battery ingestions occur in patients between 6 and 39 years of age and are intentional [",
"    <a class=\"abstract\" href=\"UTD.htm?14/62/15337/abstract/2,9\">",
"     2,9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Intact cylindrical batteries (eg, AA, AAA, C type batteries) pose a low threat for caustic damage after ingestion. Most will pass through the gastrointestinal tract without sequelae. Endoscopic removal is suggested if the battery is lodged in the esophagus or if the battery has not passed through the pylorus within 48 hours. Recommendations for follow-up radiographs to confirm passage in asymptomatic patients are the same as for button batteries. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Position distal to esophagus'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Sucking on the fluid from a leaking cylindrical battery has caused esophageal burns in a child [",
"    <a class=\"abstract\" href=\"UTD.htm?14/62/15337/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complications from button battery ingestion are rare, but potentially devastating. They include, but are not limited to, tracheoesophageal fistula, vocal cord paralysis, esophageal perforation, esophageal stenosis, mediastinitis, spondylodiscitis, aspiration pneumonia, perforation of the aortic arch, gastric hemorrhage, gastric perforation, and intestinal perforation [",
"    <a class=\"abstract\" href=\"UTD.htm?14/62/15337/abstract/2,14,17,28,49-53\">",
"     2,14,17,28,49-53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One case series of 86 patients with major outcomes (esophageal burns, perforations, or fistulas) and 13 deaths after button battery ingestion identified the following risk factors [",
"    <a class=\"abstract\" href=\"UTD.htm?14/62/15337/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Button battery diameter &ge;20 mm",
"     </li>",
"     <li>",
"      Patient younger than four years of age",
"     </li>",
"     <li>",
"      Ingestion of more than one button battery",
"     </li>",
"     <li>",
"      Unwitnessed or unknown ingestion time",
"     </li>",
"     <li>",
"      Misdiagnosis of button battery ingestion",
"     </li>",
"     <li>",
"      Delayed battery removal",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In this series, tracheoesophageal fistula or esophageal stricture were not symptomatic for many days after removal. In one case, fatal bleeding from an aortoesophageal fistula occurred 18 days after battery retrieval [",
"    <a class=\"abstract\" href=\"UTD.htm?14/62/15337/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;As with other ingestions, primary prevention of ingestion is preferable to treatment. Children and their caregivers should be educated about the dangers of button battery ingestion, proper disposal of batteries, and avoidance of the use of one's mouth as a \"third hand\" while changing batteries.",
"   </p>",
"   <p>",
"    Other measures that caregivers may consider include the following [",
"    <a class=\"abstract\" href=\"UTD.htm?14/62/15337/abstract/9\">",
"     9",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Check and secure (with tape) battery compartments on household products",
"     </li>",
"     <li>",
"      Store batteries out of reach and sight of children",
"     </li>",
"     <li>",
"      Don&rsquo;t allow children to play with batteries",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, changes in the design of button batteries",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    the products they power could prevent morbidity from ingestion. These include [",
"    <a class=\"abstract\" href=\"UTD.htm?14/62/15337/abstract/1,3,9,15\">",
"     1,3,9,15",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Developing child-resistant, unit-of-use battery packaging",
"     </li>",
"     <li>",
"      Providing package warnings regarding the potential for serious injury or death if a button battery is ingested",
"     </li>",
"     <li>",
"      Securing the battery compartment of devices using button batteries so that a tool is required to open them",
"     </li>",
"     <li>",
"      Altering the design of hearing aids and other battery-containing products that are used by children to make the battery less accessible",
"     </li>",
"     <li>",
"      Improving the integrity of the seal and crimp area of button batteries",
"     </li>",
"     <li>",
"      Eliminating button batteries greater than 15 mm in diameter (since these are more likely to lodge in the esophagus).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?14/24/14722?source=see_link\">",
"       \"Patient information: Swallowed objects (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H89411540\">",
"    <span class=\"h1\">",
"     ADDITIONAL RESOURCES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Regional poison control centers in the United States are available at all times for consultation on patients who are critically ill, require admission, or have clinical pictures that are unclear (1-800-222-1222). In addition, some hospitals have clinical",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    medical toxicologists available for bedside consultation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    inpatient care. Whenever available, these are invaluable resources to help in the diagnosis and management of ingestions or overdoses. The World Health Organization provides a listing of international poison centers at its website:",
"    <a class=\"external\" href=\"file://www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html\">",
"     www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The National Battery Ingestion Hotline (NBIH) (202-625-3333, TDD 202-362-8563) or one of the regional Poison Control Centers in the US (1-800-222-1222) is available to provide guidance for the management of patients with button battery ingestions.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Ingested button batteries have strong potential for corrosive injury to the gastrointestinal tract with major complications, including esophageal burns, fistula, or perforation. These complications are significantly associated with ingestion of batteries that are &ge;20 mm in diameter, primarily lithium cells. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H22\">",
"       'Complications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The chemical content and diameter of the battery can be determined from the imprinted code found on the battery case. This code may be known by the caregiver or can be obtained from a spare battery. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Battery identification'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most button battery ingestions are witnessed, and up to 80 percent of patients are asymptomatic at the time of presentation. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Prompt evaluation is necessary for all children under 12 years of age who ingest button batteries. The size of the battery and presence of symptoms cannot be used to reliably detect batteries lodged in the esophagus in these patients.",
"     </li>",
"     <li>",
"      Plain radiographs in anteroposterior (AP) and lateral views from the nasopharynx to the anus should be obtained to localize the battery and to detect evidence of battery fragmentation in all children &le;12 years of age, in all patients who have ingested a button battery that is &ge;12 mm in diameter, or in patients for whom the diameter of the battery is not known. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Radiographic localization'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In asymptomatic, healthy patients over 12 years of age with confirmed ingestion of a solitary battery that is &le;12 mm in diameter and without coingestion of a magnet, radiography may be deferred as long as the patient or caregiver is reliable and able to promptly seek treatment should symptoms develop. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Radiographic localization'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Batteries lodged in the esophagus must be emergently removed by endoscopy. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Esophageal position'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Other indications for endoscopic or surgical removal include signs of gastrointestinal (GI) injury (eg, hematochezia, melena, or acute abdomen), arrested transit of a large diameter (&ge;15 mm) battery in the stomach or intestines for more than 48 hours, or coingestion of a magnet. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Position distal to esophagus'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Batteries distal to the esophagus usually pass uneventfully; passage should be documented by examination of stools. Repeat radiographs should be obtained four days after ingestion in children under six years of age who have ingested a battery with a diameter &ge;15 mm. Otherwise, if the battery has not passed within 10 to 14 days of ingestion, repeat radiographs should be obtained. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Position distal to esophagus'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/62/15337/abstract/1\">",
"      Litovitz T, Schmitz BF. Ingestion of cylindrical and button batteries: an analysis of 2382 cases. Pediatrics 1992; 89:747.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/62/15337/abstract/2\">",
"      Litovitz T, Whitaker N, Clark L, et al. Emerging battery-ingestion hazard: clinical implications. Pediatrics 2010; 125:1168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/62/15337/abstract/3\">",
"      Litovitz TL. Button battery ingestions. A review of 56 cases. JAMA 1983; 249:2495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/62/15337/abstract/4\">",
"      Thompson N, Lowe-Ponsford F, Mant TG, Volans GN. Button battery ingestion: a review. Adverse Drug React Acute Poisoning Rev 1990; 9:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/62/15337/abstract/5\">",
"      Litovitz TL. Battery ingestions: product accessibility and clinical course. Pediatrics 1985; 75:469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/62/15337/abstract/6\">",
"      Mofenson HC, Greensher J, Caraccio TR, Danoff R. Ingestion of small flat disc batteries. Ann Emerg Med 1983; 12:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/62/15337/abstract/7\">",
"      Sharpe SJ, Rochette LM, Smith GA. Pediatric battery-related emergency department visits in the United States, 1990-2009. Pediatrics 2012; 129:1111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/62/15337/abstract/8\">",
"      Centers for Disease Control and Prevention (CDC). Injuries from batteries among children aged &lt;13 years--United States, 1995-2010. MMWR Morb Mortal Wkly Rep 2012; 61:661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/62/15337/abstract/9\">",
"      Litovitz T, Whitaker N, Clark L. Preventing battery ingestions: an analysis of 8648 cases. Pediatrics 2010; 125:1178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/62/15337/abstract/10\">",
"      Millar AJ, Rode H, Cywes S, Van Der Walt F. Button-battery ingestion--a hazard of modern living. S Afr Med J 1985; 68:868.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/62/15337/abstract/11\">",
"      Levine MJ, Jacob H, Rubin M. Battery ingestion: a potential form of alkaline injury to the gastrointestinal tract. Ann Emerg Med 1984; 13:143.",
"     </a>",
"    </li>",
"    <li>",
"     International electrotechnical Commission. www.iec.ch/ (Accessed on June 02, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/62/15337/abstract/13\">",
"      Langkau JF, Noesges RA. Esophageal burns from battery ingestion. Am J Emerg Med 1985; 3:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/62/15337/abstract/14\">",
"      Sigalet D, Lees G. Tracheoesophageal injury secondary to disc battery ingestion. J Pediatr Surg 1988; 23:996.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/62/15337/abstract/15\">",
"      Maves MD, Carithers JS, Birck HG. Esophageal burns secondary to disc battery ingestion. Ann Otol Rhinol Laryngol 1984; 93:364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/62/15337/abstract/16\">",
"      Yamashlta M, Saito S, Koyama K, et al. Esophageal electrochemical burn by button-type alkaline batteries in dogs. Vet Hum Toxicol 1987; 29:226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/62/15337/abstract/17\">",
"      Bass DH, Millar AJ. Mercury absorption following button battery ingestion. J Pediatr Surg 1992; 27:1541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/62/15337/abstract/18\">",
"      Rebhandl W, Steffan I, Schramel P, et al. Release of toxic metals from button batteries retained in the stomach: An in vitro study. J Pediatr Surg 2002; 37:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/62/15337/abstract/19\">",
"      Litovitz T, Butterfield AB, Holloway RR, Marion LI. Button battery ingestion: assessment of therapeutic modalities and battery discharge state. J Pediatr 1984; 105:868.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/62/15337/abstract/20\">",
"      Kost KM, Shapiro RS. Button battery ingestion: a case report and review of the literature. J Otolaryngol 1987; 16:252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/62/15337/abstract/21\">",
"      Mallon PT, White JS, Thompson RL. Systemic absorption of lithium following ingestion of a lithium button battery. Hum Exp Toxicol 2004; 23:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/62/15337/abstract/22\">",
"      Kuhns DW, Dire DJ. Button battery ingestions. Ann Emerg Med 1989; 18:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/62/15337/abstract/23\">",
"      Kulig K, Rumack CM, Rumack BH, Duffy JP. Disk battery ingestion. Elevated urine mercury levels and enema removal of battery fragments. JAMA 1983; 249:2502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/62/15337/abstract/24\">",
"      Mant TG, Lewis JL, Mattoo TK, et al. Mercury poisoning after disc-battery ingestion. Hum Toxicol 1987; 6:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/62/15337/abstract/25\">",
"      Reilly DT. Mercury battery ingestion. Br Med J 1979; 1:859.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/62/15337/abstract/26\">",
"      D'Sa Barros EA, D'Sa Barros AA. Mercury battery ingestion. Br Med J 1979; 1:1218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/62/15337/abstract/27\">",
"      Barber TE, Menke RD. The relationship of ingested iron to the absorption of mercuric oxide. Am J Emerg Med 1984; 2:500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/62/15337/abstract/28\">",
"      Samad L, Ali M, Ramzi H. Button battery ingestion: hazards of esophageal impaction. J Pediatr Surg 1999; 34:1527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/62/15337/abstract/29\">",
"      David TJ, Ferguson AP. Management of children who have swallowed button batteries. Arch Dis Child 1986; 61:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/62/15337/abstract/30\">",
"      Shastri N, Leys C, Fowler M, Conners GP. Pediatric button battery and small magnet coingestion: two cases with different outcomes. Pediatr Emerg Care 2011; 27:642.",
"     </a>",
"    </li>",
"    <li>",
"     \"NBIH Button battery ingestion triage and treatment guideline\". National Captial Poison Center. www.poison.org/battery/guideline.asp (Accessed on June 01, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/62/15337/abstract/32\">",
"      Rumack BH, Rumack CM. Disk battery ingestion. JAMA 1983; 249:2509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/62/15337/abstract/33\">",
"      Maves MD, Lloyd TV, Carithers JS. Radiographic identification of ingested disc batteries. Pediatr Radiol 1986; 16:154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/62/15337/abstract/34\">",
"      Bernstein JM, Burrows SA, Saunders MW. Lodged oesophageal button battery masquerading as a coin: an unusual cause of bilateral vocal cord paralysis. Emerg Med J 2007; 24:e15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/62/15337/abstract/35\">",
"      Webb WA. Management of foreign bodies of the upper gastrointestinal tract: update. Gastrointest Endosc 1995; 41:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/62/15337/abstract/36\">",
"      Temple DM, McNeese MC. Hazards of battery ingestion. Pediatrics 1983; 71:100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/62/15337/abstract/37\">",
"      Gordon AC, Gough MH. Oesophageal perforation after button battery ingestion. Ann R Coll Surg Engl 1993; 75:362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/62/15337/abstract/38\">",
"      Brumbaugh DE, Colson SB, Sandoval JA, et al. Management of button battery-induced hemorrhage in children. J Pediatr Gastroenterol Nutr 2011; 52:585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/62/15337/abstract/39\">",
"      Kimball SJ, Park AH, Rollins MD 2nd, et al. A review of esophageal disc battery ingestions and a protocol for management. Arch Otolaryngol Head Neck Surg 2010; 136:866.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/62/15337/abstract/40\">",
"      Soccorso G, Grossman O, Martinelli M, et al. 20 mm lithium button battery causing an oesophageal perforation in a toddler: lessons in diagnosis and treatment. Arch Dis Child 2012; 97:746.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/62/15337/abstract/41\">",
"      McDermott VG, Taylor T, Wyatt JP, et al. Orogastric magnet removal of ingested disc batteries. J Pediatr Surg 1995; 30:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/62/15337/abstract/42\">",
"      Jaffe RB, Corneli HM. Fluoroscopic removal of ingested alkaline batteries. Radiology 1984; 150:585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/62/15337/abstract/43\">",
"      Ito Y, Ihara N, Sohma S. Magnetic removal of alkaline batteries from the stomach. J Pediatr Surg 1985; 20:250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/62/15337/abstract/44\">",
"      Rivera EA, Maves MD. Effects of neutralizing agents on esophageal burns caused by disc batteries. Ann Otol Rhinol Laryngol 1987; 96:362.",
"     </a>",
"    </li>",
"    <li>",
"     Aronow, R. Mercury. In: Clinical Management of poisoning and Drug Overdose, 2nd, Haddad, LM (Eds), WB Saunders, Philadelphia 1990. p.1004.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/62/15337/abstract/46\">",
"      Lavelle-Jones M, Lyall MH, McCollum P, Cuschieri A. Disc battery ingestion: a review and a management plan. J R Coll Surg Edinb 1992; 37:120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/62/15337/abstract/47\">",
"      Namasivayam S. Button battery ingestion: a solution to a management dilemma. Pediatr Surg Int 1999; 15:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/62/15337/abstract/48\">",
"      Untersweg U, Mayr J, Schmidt B. Oesophageal burn caused by sucking a 1.5 volt battery. Acta Paediatr 1996; 85:1382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/62/15337/abstract/49\">",
"      Wall SJ, Nadel DM, Handler SD. Airway compromise caused by disk battery ingestion. Otolaryngol Head Neck Surg 1999; 121:302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/62/15337/abstract/50\">",
"      Anand TS, Kumar S, Wadhwa V, Dhawan R. Rare case of spontaneous closure of tracheo-esophageal fistula secondary to disc battery ingestion. Int J Pediatr Otorhinolaryngol 2002; 63:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/62/15337/abstract/51\">",
"      Chiang MC, Chen YS. Tracheoesophageal fistula secondary to disc battery ingestion. Am J Otolaryngol 2000; 21:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/62/15337/abstract/52\">",
"      Willis GA, Ho WC. Perforation of Meckel's diverticulum by an alkaline hearing aid battery. Can Med Assoc J 1982; 126:497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/62/15337/abstract/53\">",
"      Alkan M, B&uuml;y&uuml;kyavuz I, Doru D, et al. Tracheoesophageal fistula due to disc-battery ingestion. Eur J Pediatr Surg 2004; 14:274.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6497 Version 13.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-61.234.146.186-EC60C7DA3C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_62_15337=[""].join("\n");
var outline_f14_62_15337=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H24\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      BATTERY DESCRIPTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      BATTERY IDENTIFICATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Electrical discharge",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Leakage of contents",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Alkaline solutions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Heavy metals",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Pressure necrosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      History",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Signs and symptoms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Button batteries",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Radiographic localization",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Esophageal position",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Position distal to esophagus",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Mercury toxicity",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Unproven therapies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Cylindrical batteries",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H89411540\">",
"      ADDITIONAL RESOURCES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/6497\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6497|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?25/39/26239\" title=\"diagnostic image 1\">",
"      Battery versus coin AP radiograph",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?38/21/39263\" title=\"diagnostic image 2\">",
"      Battery versus coin lateral radiograph",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?27/54/28515\" title=\"diagnostic image 3\">",
"      Battery esophageal stenosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6497|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?15/5/15440\" title=\"figure 1\">",
"      Battery schematic",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?20/11/20659\" title=\"figure 2\">",
"      Esophageal foreign body sites",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/23/4473?source=related_link\">",
"      Caustic esophageal injury in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/53/28504?source=related_link\">",
"      Diagnosis and management of foreign bodies of the outer ear",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/21/17752?source=related_link\">",
"      Diagnosis and management of intranasal foreign bodies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/31/34295?source=related_link\">",
"      Epidemiology and toxicity of mercury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/22/1386?source=related_link\">",
"      Foreign bodies of the esophagus and gastrointestinal tract in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/54/21353?source=related_link\">",
"      Ingested foreign bodies and food impactions in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?14/24/14722?source=related_link\">",
"      Patient information: Swallowed objects (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_62_15338="Role of implantable cardioverter-defibrillators for the primary prevention of sudden cardiac death after myocardial infarction";
var content_f14_62_15338=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Role of implantable cardioverter-defibrillators for the primary prevention of sudden cardiac death after myocardial infarction",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/62/15338/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/62/15338/contributors\">",
"     Leonard I Ganz, MD, FHRS, FACC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/62/15338/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/62/15338/contributors\">",
"     Samuel L&eacute;vy, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/62/15338/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/62/15338/contributors\">",
"     Brian C Downey, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?14/62/15338/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 26, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with a history of a myocardial infarction (MI) are at increased risk for sudden cardiac death (SCD), most commonly due to a ventricular tachyarrhythmia. As a result, SCD and arrhythmic death are often used synonymously.",
"   </p>",
"   <p>",
"    The risk of SCD is highest during and immediately after an infarction, then declines in phases over the following days and months. One-quarter of arrhythmic deaths occur in the first three months and one-half within the first year after an MI [",
"    <a class=\"abstract\" href=\"UTD.htm?14/62/15338/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. The incidence of SCD eventually stabilizes at a level that is elevated compared to individuals who have never had an MI. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/10/30890?source=see_link\">",
"     \"Clinical features and treatment of ventricular arrhythmias during acute myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Because arrhythmic risks remain elevated indefinitely, prevention of SCD is among the most important considerations in patients with a history of either an ST elevation or a non-ST elevation infarction [",
"    <a class=\"abstract\" href=\"UTD.htm?14/62/15338/abstract/3\">",
"     3",
"    </a>",
"    ]. Standard medical therapies, including ACE inhibitors and beta blockers, reduce both arrhythmic and nonarrhythmic mortality rates following an MI. However, the implantable cardioverter-defibrillator (ICD) is now established as the best available therapy to prevent SCD in patients at the highest risk.",
"   </p>",
"   <p>",
"    In summary, efforts to prevent SCD after an MI include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Standard medical therapies including ACE inhibitors, beta blockers, and statins.",
"     </li>",
"     <li>",
"      Identification of those patients at greatest risk of malignant arrhythmias [",
"      <a class=\"abstract\" href=\"UTD.htm?14/62/15338/abstract/4,5\">",
"       4,5",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/24/20874?source=see_link\">",
"       \"Incidence of and risk stratification for sudden cardiac death after acute myocardial infarction\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      ICD placement in selected high-risk patients.",
"     </li>",
"     <li>",
"      Antiarrhythmic therapy in special circumstances, usually as adjunctive therapy in patients with an ICD who experience frequent shocks, or less commonly, as primary therapy in patients who are not candidates for an ICD. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/53/16217?source=see_link\">",
"       \"Role of antiarrhythmic drugs for ventricular arrhythmias in patients with a prior myocardial infarction\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Approaches to the primary prevention of SCD after an acute MI will be reviewed here. The treatment of patients who have already experienced a serious sustained ventricular arrhythmia (secondary prevention), and risk stratification for recurrent ischemic events after ST elevation and non-ST elevation infarctions are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/10/30890?source=see_link\">",
"     \"Clinical features and treatment of ventricular arrhythmias during acute myocardial infarction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/32/29193?source=see_link\">",
"     \"Sustained monomorphic ventricular tachycardia in patients with a prior myocardial infarction: Treatment and prognosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/52/35658?source=see_link\">",
"     \"Risk stratification for cardiac events after acute ST elevation myocardial infarction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/43/2746?source=see_link\">",
"     \"Risk stratification after unstable angina or non-ST elevation myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     MEDICAL THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several of the components of usual medical therapy after an MI reduce SCD as well as overall mortality. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/41/44697?source=see_link\">",
"     \"Overview of the acute management of ST elevation myocardial infarction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/20/37193?source=see_link\">",
"     \"Overview of the acute management of unstable angina and non-ST elevation myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beta blockers &ndash; Beta blockers reduce overall mortality in patients with an acute MI and, in a review of 13 trials that reported data on SCD, the average incidence was reduced from 5.0 to 3.3 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?14/62/15338/abstract/6\">",
"       6",
"      </a>",
"      ]. A similar reduction was noted in the largest of these trials (4.6 to 3.3 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?14/62/15338/abstract/6,7\">",
"       6,7",
"      </a>",
"      ]. The SCD benefit is better described in patients with chronic heart failure (HF). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/53/11098?source=see_link\">",
"       \"Beta blockers in the management of acute coronary syndrome\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/47/21241?source=see_link&amp;anchor=H13#H13\">",
"       \"Ventricular arrhythmias in heart failure and cardiomyopathy\", section on 'Beta blockers'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      The benefits of beta blockers in post-MI patients with an ICD were illustrated in a post hoc analysis from the MADIT II trial discussed below [",
"      <a class=\"abstract\" href=\"UTD.htm?14/62/15338/abstract/8\">",
"       8",
"      </a>",
"      ]. Among 691 patients who received ICDs, 433 were also treated with beta blockers. Compared to those not treated with beta blockers, patients treated with a beta blocker had a significantly lower mortality (hazard ratio [HR] 0.43) and patients in the highest quartile of beta blocker dose had a significant reduction in the risk of VT or VF requiring ICD discharge (HR 0.48).",
"     </li>",
"     <li>",
"      ACE inhibitors &ndash; A meta analysis of 15,104 patients in 15 trials of acute MI found that ACE inhibitor therapy reduced the risk of SCD (odds ratio 0.80, absolute benefit about 1.4 percent) as well as overall and cardiovascular mortality (odds ratio 0.82) [",
"      <a class=\"abstract\" href=\"UTD.htm?14/62/15338/abstract/9\">",
"       9",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/30/26088?source=see_link\">",
"       \"Angiotensin converting enzyme inhibitors and receptor blockers in acute myocardial infarction: Clinical trials\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Angiotensin II receptor blockers &ndash; Angiotensin II receptor blockers (ARBs) are given to patients who cannot tolerate ACE inhibitors. At appropriate doses, it is likely that ARBs reduce the risk of SCD to the same degree as ACE inhibitors [",
"      <a class=\"abstract\" href=\"UTD.htm?14/62/15338/abstract/10\">",
"       10",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/55/13175?source=see_link\">",
"       \"Angiotensin converting enzyme inhibitors and receptor blockers in acute myocardial infarction: Recommendations for use\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Statins &ndash; Statins given to patients who have had an acute MI improve overall mortality. Although data are limited, part of the benefit seems to result from a lower rate of SCD, which may reflect a direct effect of statin therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?14/62/15338/abstract/11-13\">",
"       11-13",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/55/33656?source=see_link\">",
"       \"Cholesterol lowering after an acute coronary syndrome\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/23/3448?source=see_link&amp;anchor=H2100326#H2100326\">",
"       \"Pharmacologic therapy in survivors of sudden cardiac arrest\", section on 'Lipid-lowering'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Aldosterone antagonists &ndash; Among post-MI patients who have left ventricular (LV) dysfunction and HF",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      diabetes,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5031?source=see_link\">",
"       eplerenone",
"      </a>",
"      significantly reduced both overall mortality and SCD mortality (4.9 versus 6.1 percent, relative risk 0.79) [",
"      <a class=\"abstract\" href=\"UTD.htm?14/62/15338/abstract/14\">",
"       14",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/54/28521?source=see_link&amp;anchor=H4#H4\">",
"       \"Use of aldosterone antagonists in heart failure\", section on 'Eplerenone in EPHESUS trial'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Fish intake and fish oil &ndash; There is suggestive evidence that dietary fish intake and fish oil supplementation are associated with a lower incidence of SCD, especially in populations characterized by a low fish intake [",
"      <a class=\"abstract\" href=\"UTD.htm?14/62/15338/abstract/15,16\">",
"       15,16",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/55/890?source=see_link&amp;anchor=H25#H25\">",
"       \"Overview of sudden cardiac arrest and sudden cardiac death\", section on 'Fish intake and fish oil'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     RISK STRATIFICATION STRATEGIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Until recently, risk stratification has involved identification of those at the greatest risk of SCD. However, expanding indications for ICD therapy have generated interest in the identification of low-risk individuals within otherwise high-risk cohorts.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     High-risk patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of clinical features have been evaluated as a means for identifying patients at the greatest risk of SCD following an acute MI. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Spontaneous ventricular premature beats (VPBs) and nonsustained ventricular tachycardia (NSVT)",
"     </li>",
"     <li>",
"      Reduced LV ejection fraction (LVEF)",
"     </li>",
"     <li>",
"      Late potentials on a signal averaged ECG (SAECG)",
"     </li>",
"     <li>",
"      Ventricular tachycardia (VT) induced by electrophysiologic study (EPS)",
"     </li>",
"     <li>",
"      Reduced heart rate variability (HRV)",
"     </li>",
"     <li>",
"      Microvolt T wave (repolarization) alternans (TWA)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A detailed discussion of the utility of these findings is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/24/20874?source=see_link\">",
"     \"Incidence of and risk stratification for sudden cardiac death after acute myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In a study of more than 45,000 recipients of an ICD for all primary prevention indications between 2005 and 2007 (both ischemic and non-ischemic causes of cardiomyopathy) which included development and validation cohorts (17,991 and 27,893 patients, respectively), several predictors of increased all-cause mortality, denoted by the acronym \"SHOCKED\", were identified [",
"    <a class=\"abstract\" href=\"UTD.htm?14/62/15338/abstract/17\">",
"     17",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Seventy-five years of age or older (hazard ratio [HR] 1.70, 95% CI 1.62-1.79)",
"     </li>",
"     <li>",
"      Heart failure with NYHA class III (HR 1.35, 95% CI 1.29-1.42)",
"     </li>",
"     <li>",
"      Out of rhythm from atrial fibrillation (HR 1.26, 95% CI 1.19-1.33)",
"     </li>",
"     <li>",
"      Chronic obstructive pulmonary disease (HR 1.70, 95% CI 1.61-1.80)",
"     </li>",
"     <li>",
"      Kidney disease, chronic (HR 2.33, 95% CI 2.20-2.47)",
"     </li>",
"     <li>",
"      Ejection fraction (LV) 20 percent or lower (HR 1.26, 95% CI 1.20-1.33)",
"     </li>",
"     <li>",
"      Diabetes mellitus (HR 1.43, 95% CI 1.36-1.50)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These findings allow for quick estimates of all-cause mortality using readily identifiable markers. Additionally, these markers may allow for the identification of patients at highest risk of mortality in the two to three years following ICD implantation, a group of patients who generally derive little or no benefit from the ICD.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Identification of low-risk patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;Expanding indications for ICD implantation pose clinical and economic challenges [",
"    <a class=\"abstract\" href=\"UTD.htm?14/62/15338/abstract/18\">",
"     18",
"    </a>",
"    ]. As a result, it would be useful to develop refined risk stratification tools that identify low-risk patients who may not require ICD therapy despite meeting current indications (eg, MADIT II or SCD-HeFT) for placement. Microvolt TWA has shown the most promise for identifying low-risk patients in high-risk cohorts, although clinical trials are still ongoing. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/48/5898?source=see_link&amp;anchor=H11#H11\">",
"     \"T wave (repolarization) alternans: Clinical aspects\", section on 'Identifying a low-risk subgroup from identified high-risk patients'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Timing",
"    </span>",
"    &nbsp;&mdash;&nbsp;When considering ICD placement for primary prevention in a patient with a prior myocardial infarction, timing in relation to two events is important:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Time since the most recent myocardial infarction &ndash; Although the risk of arrhythmic events is highest in the first days and weeks after an MI, early ICD therapy (ie, within 40 days of the MI) did not improve mortality in the two randomized trials that directly addressed this question. The MADIT-II substudy also suggested that survival benefit in patients receiving ICD was greater in patients whose index MI was more remote [",
"      <a class=\"abstract\" href=\"UTD.htm?14/62/15338/abstract/19\">",
"       19",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Trials early post MI'",
"      </a>",
"      below and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/24/20874?source=see_link&amp;anchor=H3#H3\">",
"       \"Incidence of and risk stratification for sudden cardiac death after acute myocardial infarction\", section on 'Time after MI'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Time since the most recent revascularization procedure &ndash; ICD implantation for primary prevention of SCD is not recommended until at least three months after a revascularization procedure. This recommendation is based primarily upon the exclusion of such patients from the ICD trials, suggesting that the results of these trials may not apply to such patients. Furthermore, in a post-hoc analysis from the MADIT II trial, benefit from ICD therapy was only seen in those patients enrolled more than six months after a revascularization procedure [",
"      <a class=\"abstract\" href=\"UTD.htm?14/62/15338/abstract/20\">",
"       20",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The inability to demonstrate a benefit from ICD therapy early after an MI or revascularization may be due to the heterogeneous nature of these populations, which include both patients at lower risk than they initially appear (eg, those destined to recover a significant degree of LV function), and patients at very high-risk in whom mortality rates are high regardless of therapy. Thus, the lack of benefit of ICD implantation early after an MI or revascularization may reflect the inability to identify patients whose long-term risk profile merits ICD therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Impact of age and comorbidities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because of the risks of noncardiac death, elderly patients and those with multiple or severe comorbidities may be less likely to derive benefit from an ICD. As an example, a post hoc analysis from the MADIT-II trial described below found no mortality benefit in patients with an estimated glomerular filtration rate less than 35",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    (mean 29",
"    <span class=\"nowrap\">",
"     mL/min,",
"    </span>",
"    no patient was on dialysis), while a benefit was noted in patients with better renal function [",
"    <a class=\"abstract\" href=\"UTD.htm?14/62/15338/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Elderly patients (eg, age &ge;75 or 80 years), were excluded from some of the major ICD trials, and few patients over age 75 were enrolled in any of the studies. It is not known, therefore, what survival benefit elderly patients derive from ICD implantation. The overall prognosis of elderly patients with an ICD was evaluated in a series of 107 patients &ge;80 years of age at the time of ICD implantation [",
"    <a class=\"abstract\" href=\"UTD.htm?14/62/15338/abstract/22\">",
"     22",
"    </a>",
"    ]. Median survival after implantation was &gt;4 years, but among those patients with an LVEF &le;30 percent and an estimated glomerular filtration rate &lt;60",
"    <span class=\"nowrap\">",
"     mL/min,",
"    </span>",
"    median survival was &lt;2 years. As there was no control group, this study could not determine whether or not elderly patients derived survival benefit from an ICD. Rather, it showed that some patients over age 80 can be expected to live long enough that an ICD may improve overall survival, while those with severe disease and comorbidities have a poor prognosis even with an ICD.",
"   </p>",
"   <p>",
"    Further research in this area is needed, and specific disqualifying comorbidities for ICD therapy have not been defined. The Center for Medicare Services (CMS) require that a patient have an expected survival of at least one year to qualify for ICD therapy. Patients with shorter expected survivals were excluded from the ICD trials.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     ICD TRIALS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ICD is currently the optimal method for preventing SCD in selected high-risk post-MI patients. The benefit of ICD implantation has been established in randomized clinical trials, including MUSTT, MADIT I, MADIT II, and SCD-HeFT [",
"    <a class=\"abstract\" href=\"UTD.htm?14/62/15338/abstract/23-26\">",
"     23-26",
"    </a>",
"    ], and supported by observational studies of clinical practice [",
"    <a class=\"abstract\" href=\"UTD.htm?14/62/15338/abstract/27\">",
"     27",
"    </a>",
"    ]. These trials are discussed in detail separately, but will be briefly reviewed here. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/12/19657?source=see_link\">",
"     \"Implantable cardioverter-defibrillators: Clinical trials of primary prevention of sudden cardiac death\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A review of these trials illustrates the evolution of indications for an ICD. These trials defined, by their inclusion criteria, populations in which ICDs confer mortality benefit. However, they did not directly compare the relative importance of various risk factors or the efficacy of different risk stratification algorithms. As a result, an optimal risk stratification strategy has not been defined.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     MUSTT and MADIT trials",
"    </span>",
"    &nbsp;&mdash;&nbsp;The MUSTT and MADIT trials demonstrated the efficacy of ICD therapy for primary prevention in high-risk patients with the following features [",
"    <a class=\"abstract\" href=\"UTD.htm?14/62/15338/abstract/23-25\">",
"     23-25",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Prior myocardial infarction",
"     </li>",
"     <li>",
"      Reduced LVEF (&le;40 percent in MUSTT, &le;35 percent in MADIT I, and &le;30 percent in MADIT II)",
"     </li>",
"     <li>",
"      NSVT",
"     </li>",
"     <li>",
"      Inducible ventricular arrhythmias at EP study",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The MUSTT and MADIT II trials involved different study protocols. Both studies enrolled patients with inducible VT or VF, but in MUSTT, patients were randomly assigned to standard medical therapy or to EPS-guided therapy which could have been either an ICD or antiarrhythmic drugs, while in MADIT, patients with inducible VT or VF that was not suppressed by",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/34/36391?source=see_link\">",
"     procainamide",
"    </a>",
"    were randomly assigned to an ICD or to standard medical therapy, which could include an antiarrhythmic drug.",
"   </p>",
"   <p>",
"    Both trials demonstrated mortality benefit from ICD therapy. In MUSTT, patients assigned to EPS-guided therapy had lower rates of SCD, but this benefit was seen only in patients who received an ICD [",
"    <a class=\"abstract\" href=\"UTD.htm?14/62/15338/abstract/23\">",
"     23",
"    </a>",
"    ]. Patients assigned to EPS but treated with an antiarrhythmic showed no improvement compared to controls (",
"    <a class=\"graphic graphic_figure graphicRef68247 \" href=\"UTD.htm?1/34/1582\">",
"     figure 1",
"    </a>",
"    ). Similarly, in MADIT I, patients assigned to ICD therapy had significant reductions in the incidence of overall mortality, cardiac mortality, and arrhythmic deaths (",
"    <a class=\"graphic graphic_figure graphicRef76854 \" href=\"UTD.htm?38/48/39693\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/62/15338/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    On the basis of these results, ICD therapy is indicated in patients with an LVEF &le;40 percent, NSVT, and inducible VT or VF. Whether or not the ability to induce VT or VF is suppressed by an antiarrhythmic is no longer considered a useful method of risk stratification.",
"   </p>",
"   <p>",
"    Patients with a prior MI and severe systolic dysfunction (LVEF &le;30 percent) have a high risk of SCD regardless of the presence of NSVT or the results of EPS. MADIT II demonstrated that such patients derive survival benefit from ICD therapy (",
"    <a class=\"graphic graphic_figure graphicRef63529 \" href=\"UTD.htm?19/35/20029\">",
"     figure 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/62/15338/abstract/25,28\">",
"     25,28",
"    </a>",
"    ]. However, the absolute reduction in mortality was less than in MUSTT and MADIT I. The number needed to treat to prevent one death were three over five years, four over five years, and 18 over 20 months in MUSTT, MADIT I, and MADIT II, respectively.",
"   </p>",
"   <p>",
"    Due in part to the lower absolute benefit reported in MADIT II patients, efforts are now focused on evaluating factors that may refine indications by identifying low-risk patients in otherwise high-risk cohorts. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Identification of low-risk patients'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;The benefits from ICD therapy compared to the control group in these post-MI trials can be summarized as follows [",
"    <a class=\"abstract\" href=\"UTD.htm?14/62/15338/abstract/29\">",
"     29",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For SCD &ndash; relative risks of 0.29, 0.25, and 0.39 in MUSTT, MADIT I, and MADIT II, respectively; all were significant",
"     </li>",
"     <li>",
"      For all-cause mortality &ndash; relative risks of 0.49, 0.41, and 0.71 in MUSTT, MADIT I, and MADIT II, respectively; all were significant",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Trials early post MI",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the risk of death, including SCD is highest early after MI, the DINAMIT AND IRIS trials failed to show a reduction in overall mortality from ICD implantation within the first month after MI [",
"    <a class=\"abstract\" href=\"UTD.htm?14/62/15338/abstract/30,31\">",
"     30,31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The results of MUSTT and MADIT trials do not apply to patients within the first weeks of MI since most of the patients in these trials were enrolled several years after their infarction. In MUSTT, the most recent MI occurred within the previous month in only 17 percent of patients and more than three years previously in one-half [",
"    <a class=\"abstract\" href=\"UTD.htm?14/62/15338/abstract/23\">",
"     23",
"    </a>",
"    ]. In MADIT I and MADIT II, the most recent MI occurred within the previous six months in only 24 and 12 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?14/62/15338/abstract/24,25\">",
"     24,25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The reasons for the lack of benefit of ICD therapy in DINAMIT and IRIS trials compared to the MADIT and MUSTT trials are not clear. Possible explanations are discussed in detail separately [",
"    <a class=\"abstract\" href=\"UTD.htm?14/62/15338/abstract/32\">",
"     32",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/12/19657?source=see_link&amp;anchor=H9#H9\">",
"     \"Implantable cardioverter-defibrillators: Clinical trials of primary prevention of sudden cardiac death\", section on 'Early post MI trials'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/24/20874?source=see_link&amp;anchor=H3#H3\">",
"     \"Incidence of and risk stratification for sudden cardiac death after acute myocardial infarction\", section on 'Time after MI'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     DINAMIT trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of prophylactic ICD implantation in the first weeks after an MI was evaluated in the DINAMIT trial which enrolled 332 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?14/62/15338/abstract/30\">",
"     30",
"    </a>",
"    ]. Inclusion criteria included an MI within the preceding 6 to 40 days (mean 18 days), an LVEF &le;35 percent and either reduced heart rate variability or elevated resting heart rate (&ge;80",
"    <span class=\"nowrap\">",
"     beats/min).",
"    </span>",
"    Mean follow-up was 30 months. In contrast to the MUSTT and MADIT trials, there was no difference in annual all-cause mortality between the ICD patients and controls (7.5 versus 6.9 percent). Arrhythmic deaths were more frequent in the control arm, while nonarrhythmic deaths were more frequent in the ICD arm.",
"   </p>",
"   <p>",
"    The lack of benefit in DINAMIT is the primary reason that current guidelines recommend that ICD implantation should be deferred until at least 40 days after an MI.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     IRIS trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;The results of the DINAMIT trial were confirmed by the IRIS trial which enrolled 898 patients within 5 to 31 days following MI [",
"    <a class=\"abstract\" href=\"UTD.htm?14/62/15338/abstract/31\">",
"     31",
"    </a>",
"    ]. Inclusion criteria included criterion 1 (LVEF &le;40 percent and a resting heart rate &ge;90",
"    <span class=\"nowrap\">",
"     beats/min)",
"    </span>",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    criterion 2 (nonsustained ventricular tachycardia &ge;150",
"    <span class=\"nowrap\">",
"     beats/min).",
"    </span>",
"    Mean follow-up was 37 months. Similar to the DINAMIT trial, there was no difference in all-cause mortality between patients randomly assigned to ICD therapy and those assigned to medical therapy. The rate of SCD was higher in the control group but the number of nonsudden cardiac deaths was higher in the ICD arm.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     SCD-HeFT trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;The SCD-HeFT trial examined the role of an ICD in patients with chronic stable HF due to either an ischemic or nonischemic cardiomyopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?14/62/15338/abstract/26\">",
"     26",
"    </a>",
"    ]. Important distinctions from earlier trials include the requirement that patients have symptomatic HF and also the enrollment of patients with nonischemic cardiomyopathy. Ischemic cardiomyopathy, with focal myocardial scar from prior infarctions, represents a distinct form of arrhythmic substrate. Patients with nonischemic cardiomyopathy have a different pathology, and may also have a higher incidence of nonarrhythmic death (eg, from progressive HF). For these reasons, it was not clear if patients with nonischemic cardiomyopathy would derive survival benefit from an ICD. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/55/19322?source=see_link&amp;anchor=H15#H15\">",
"     \"Secondary and primary prevention of sudden cardiac death in heart failure and cardiomyopathy\", section on 'Ischemic cardiomyopathy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In SCD-HeFT, patients with an LVEF &le;35 percent and NYHA class II or III HF (",
"    <a class=\"graphic graphic_table graphicRef52683 \" href=\"UTD.htm?3/2/3117\">",
"     table 1",
"    </a>",
"    ) were randomly assigned to ICD implantation,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    , or placebo. Overall mortality at five years was significantly reduced with ICD therapy (29 versus 36 percent with placebo) but not with amiodarone. The benefit of an ICD was not significantly different with an ischemic or nonischemic cardiomyopathy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/12/19657?source=see_link&amp;anchor=H8#H8\">",
"     \"Implantable cardioverter-defibrillators: Clinical trials of primary prevention of sudden cardiac death\", section on 'SCD-HeFT trial'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/12/19657?source=see_link&amp;anchor=H16#H16\">",
"     \"Implantable cardioverter-defibrillators: Clinical trials of primary prevention of sudden cardiac death\", section on 'SCD-HeFT and nonischemic cardiomyopathy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    With regard to patients with ischemic cardiomyopathy, the following findings from SCD-HeFT expand upon the results of prior trials:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"       Amiodarone",
"      </a>",
"      did not reduce mortality in patients with at least moderate LV dysfunction and HF.",
"     </li>",
"     <li>",
"      An ICD is beneficial in patients with symptomatic HF, which was present in all patients in SCD-HeFT as opposed to two-thirds of patients in MADIT II.",
"     </li>",
"     <li>",
"      The benefit of an ICD may be greater in patients with a QRS duration &ge;120 msec (HR 0.67) than in those with a QRS duration &lt;120 msec (HR 0.84). A similar relationship was suggested in MADIT II [",
"      <a class=\"abstract\" href=\"UTD.htm?14/62/15338/abstract/25\">",
"       25",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, the results of SCD-HeFT in patients with an ischemic cardiomyopathy reinforce the principal findings of MADIT II and extend the indications for ICD to patients with an ischemic cardiomyopathy, NYHA class II to III HF, and an LVEF &le;35 percent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     COMPANION trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cardiac resynchronization therapy (CRT) with biventricular pacing may be appropriate treatment for HF in selected patients after an MI. Ventricular dyssynchrony refers to the loss of coordinated contraction across the left ventricle. Dyssynchrony can further impair the pump function of a failing ventricle and exacerbate heart failure symptoms. CRT can improve pump performance, reverse the deleterious process of ventricular remodeling, and improve survival in appropriately selected patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/56/18314?source=see_link\">",
"     \"Cardiac resynchronization therapy in heart failure: Indications\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Because the indications for CRT are similar to those for an ICD, many patients have indications for a combined device with both capabilities. The COMPANION trial demonstrated the benefit of CRT with or without an ICD in 1520 patients with NYHA class III-IV HF (",
"    <a class=\"graphic graphic_table graphicRef52683 \" href=\"UTD.htm?3/2/3117\">",
"     table 1",
"    </a>",
"    ) and an LVEF &le;35 percent who had had a hospitalization for HF within the year prior to enrollment [",
"    <a class=\"abstract\" href=\"UTD.htm?14/62/15338/abstract/33\">",
"     33",
"    </a>",
"    ]. Approximately one-half of these patients had an ischemic etiology of HF. Based upon the results of the COMPANION trial, the United States Food and Drug Administration (FDA) approved the use of combination devices in patients who meet criteria for a BiV pacemaker. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/12/19657?source=see_link&amp;anchor=H19#H19\">",
"     \"Implantable cardioverter-defibrillators: Clinical trials of primary prevention of sudden cardiac death\", section on 'ICD combined with CRT'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     EVOLVING INDICATIONS FOR AN ICD FOLLOWING MYOCARDIAL INFARCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Indications for ICD therapy for the purpose of primary prevention are evolving. Guidelines from European and American societies have generally followed the results of the major clinical trials.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     ACC/AHA/ESC and ACC/AHA/HRS guidelines",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recommendations regarding ICD therapy in patients who have had an MI were included in the 2006 American College of",
"    <span class=\"nowrap\">",
"     Cardiology/American",
"    </span>",
"    Heart",
"    <span class=\"nowrap\">",
"     Association/European",
"    </span>",
"    Society of Cardiology",
"    <span class=\"nowrap\">",
"     (ACC/AHA/ESC)",
"    </span>",
"    guidelines for the management of ventricular arrhythmias and the prevention of sudden cardiac death [",
"    <a class=\"abstract\" href=\"UTD.htm?14/62/15338/abstract/34\">",
"     34",
"    </a>",
"    ], and in the 2008 American College of",
"    <span class=\"nowrap\">",
"     Cardiology/American",
"    </span>",
"    Heart",
"    <span class=\"nowrap\">",
"     Association/Heart",
"    </span>",
"    Rhythm Society",
"    <span class=\"nowrap\">",
"     (ACC/AHA/HRS)",
"    </span>",
"    guidelines for device-based therapy of cardiac rhythm abnormalities [",
"    <a class=\"abstract\" href=\"UTD.htm?14/62/15338/abstract/35\">",
"     35",
"    </a>",
"    ]. In addition to ICD therapy, the 2006",
"    <span class=\"nowrap\">",
"     ACC/AHA/ESC",
"    </span>",
"    guidelines reviewed a comprehensive range of options for the prevention and treatment of ventricular arrhythmias (eg, antiarrhythmic drugs, ablation, revascularization, and medical treatment of ischemia and heart failure).",
"   </p>",
"   <p>",
"    In contrast, the 2008",
"    <span class=\"nowrap\">",
"     ACC/AHA/HRS",
"    </span>",
"    guidelines exclusively addressed the role of ICD therapy. Thus, the 2008 guidelines do not completely replace those of 2006, but they do update the recommendations for ICD implantation. Furthermore, as the ESC did not coauthor the 2008 guidelines, the 2006 guidelines represent the most recent recommendations for ICD implantation from this organization.",
"   </p>",
"   <p>",
"    The recommendations for ICD implantation in the 2008",
"    <span class=\"nowrap\">",
"     ACC/AHA/HRS",
"    </span>",
"    guidelines are stricter than those of 2006, with closer adherence to the patient profiles defined by the inclusion criteria of important randomized trials [",
"    <a class=\"abstract\" href=\"UTD.htm?14/62/15338/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. Our approach is in general agreement with the 2008 guidelines.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     General ICD indications",
"    </span>",
"    &nbsp;&mdash;&nbsp;According to the 2008",
"    <span class=\"nowrap\">",
"     ACC/AHA/HRS",
"    </span>",
"    guidelines, the following basic criteria are required before ICD therapy should be considered:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      LV dysfunction due to a prior MI (only applies to patients with ischemic heart disease as their indication for an ICD)",
"     </li>",
"     <li>",
"      At least 40 days have passed since the most recent MI",
"     </li>",
"     <li>",
"      Optimization of medical therapy",
"     </li>",
"     <li>",
"      Expected survival with a good functional status of at least one year",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Among such patients:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There is evidence",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      general agreement that ICD therapy is appropriate for those with an LVEF &lt;35 percent and NYHA class II or III HF (",
"      <a class=\"graphic graphic_table graphicRef52683 \" href=\"UTD.htm?3/2/3117\">",
"       table 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      There is evidence",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      general agreement that ICD therapy is appropriate for those with an LVEF &le;30 percent and NYHA class I HF.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although the LVEF cutoffs in the first recommendation is &lt;35 percent, the clinical trials upon which this recommendations is based (SCD-HeFT) included patients with LVEFs &le;35 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?14/62/15338/abstract/26\">",
"     26",
"    </a>",
"    ]. We recommend adherence to the clinical trial criteria and using the cutoff of LVEF &le;35 percent.",
"   </p>",
"   <p>",
"    The guideline recommendations for ICD implantation are similar to the ICD indications outlined by the centers for medicare services (CMS). (See",
"    <a class=\"local\" href=\"#H20\">",
"     'Center for Medicare Services'",
"    </a>",
"    below.) An important exception involves the temporal relationship between revascularization and ICD implantation. According to CMS, assessment of LV function",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    severity of HF for the purpose of assessing the need for an ICD should be done at least three months after the most recent revascularization procedure (either percutaneous or surgical). Although the 2008",
"    <span class=\"nowrap\">",
"     ACC/AHA/HRS",
"    </span>",
"    guidelines do recommend delaying ICD implantation for 40 days after an acute MI, they do not require waiting three months after revascularization.",
"   </p>",
"   <p>",
"    The role of an ICD is controversial for the indications that were not present in any of the trials. Such indications include lower risk patients who some experts have believed might not benefit from ICD therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?14/62/15338/abstract/5,36\">",
"     5,36",
"    </a>",
"    ]. The arguments in favor and against ICD therapy in all patients who meet MADIT II criteria were summarized in May 2005 [",
"    <a class=\"abstract\" href=\"UTD.htm?14/62/15338/abstract/37,38\">",
"     37,38",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Identification of low-risk patients'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Cardiac resynchronization",
"    </span>",
"    &nbsp;&mdash;&nbsp;The COMPANION trial demonstrated the benefit of a device with both ICD and CRT capabilities in patients with NYHA class III-IV HF (",
"    <a class=\"graphic graphic_table graphicRef52683 \" href=\"UTD.htm?3/2/3117\">",
"     table 1",
"    </a>",
"    ), an LVEF &le;35 percent, and evidence of LV dyssynchrony. These results affect patients with NYHA class IV HF who were excluded from SCD-HeFT. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'COMPANION trial'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The 2008",
"    <span class=\"nowrap\">",
"     ACC/AHA/HRS",
"    </span>",
"    guidelines suggest that there is evidence",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    general agreement that CRT, with or without ICD therapy, is appropriate in patients meeting all of the following criteria [",
"    <a class=\"abstract\" href=\"UTD.htm?14/62/15338/abstract/35\">",
"     35",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      NYHA class III or ambulatory class IV heart failure",
"     </li>",
"     <li>",
"      Optimization of medical therapy",
"     </li>",
"     <li>",
"      Sinus rhythm",
"     </li>",
"     <li>",
"      QRS complex of at least 120 msec in duration",
"     </li>",
"     <li>",
"      Expected survival with a good functional status of at least one year",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The guidelines also stated that the weight of evidence and opinion is in favor of CRT in patients who meet the above criteria with the following exceptions:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Atrial fibrillation rather than sinus rhythm",
"     </li>",
"     <li>",
"      QRS less than 120 msec in duration, but frequent dependence on ventricular pacing",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The guidelines do not include recommendations regarding which patients meeting criteria for CRT should be treated with a device that includes both CRT and ICD capabilities. We suggest that most patients who meet the above criteria for CRT should be treated with a combination device, excluding primarily those with advanced noncardiac disease who are not expected to survive for longer one year and those who do not desire an ICD.",
"   </p>",
"   <p>",
"    Issues related to CRT are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/56/18314?source=see_link\">",
"     \"Cardiac resynchronization therapy in heart failure: Indications\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Center for Medicare Services",
"    </span>",
"    &nbsp;&mdash;&nbsp;Based upon the results of MADIT II, SCD-HeFT, DINAMIT, and COMPANION, the CMS expanded the indications for ICD insertion in January 2005 [",
"    <a class=\"abstract\" href=\"UTD.htm?14/62/15338/abstract/39,40\">",
"     39,40",
"    </a>",
"    ]. The indications include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Documented prior MI, LVEF &le;35 percent, and inducible sustained VT or VF on EP study; the MI must have occurred more than four weeks previously and the EP study must be performed more than four weeks after the MI (MADIT I criteria).",
"     </li>",
"     <li>",
"      Documented prior MI and LVEF &le;30 percent (MADIT II criteria).",
"     </li>",
"     <li>",
"      Ischemic dilated cardiomyopathy, documented prior MI, NYHA class II or III HF (",
"      <a class=\"graphic graphic_table graphicRef52683 \" href=\"UTD.htm?3/2/3117\">",
"       table 1",
"      </a>",
"      ), and LVEF &le;35 percent (SCD-HeFT criteria).",
"     </li>",
"     <li>",
"      Patients who meet all current CMS coverage requirements for a CRT device and have NYHA class IV HF (COMPANION criteria). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/56/18314?source=see_link&amp;anchor=H19#H19\">",
"       \"Cardiac resynchronization therapy in heart failure: Indications\", section on 'Indications'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Exclusions include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Prior MI within the past 40 days (DINAMIT criteria)",
"     </li>",
"     <li>",
"      Hypotension or cardiogenic shock while in a stable baseline rhythm",
"     </li>",
"     <li>",
"      CABG or PCI within the past three months",
"     </li>",
"     <li>",
"      Symptoms or findings that would make the patient a candidate for revascularization",
"     </li>",
"     <li>",
"      Noncardiac disease associated with expected survival or less than one year or irreversible brain damage.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     UTILIZATION AND OUTCOMES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sex and racial differences in ICD use for primary prevention have been reported but the available studies have important flaws [",
"    <a class=\"abstract\" href=\"UTD.htm?14/62/15338/abstract/41-43\">",
"     41-43",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In an analysis of ICD use from 1999 to 2005 in a Medicare population with prior MI and either HF or cardiomyopathy, men were 3.2 times more likely than women to receive ICD therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?14/62/15338/abstract/41\">",
"       41",
"      </a>",
"      ]. No mortality benefit from ICD use for primary prevention was found. However, LVEF data were not available so impact of LVEF on rates of use among men and women as well as on mortality rates could not be assessed [",
"      <a class=\"abstract\" href=\"UTD.htm?14/62/15338/abstract/43\">",
"       43",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In an analysis of 13,034 potentially eligible HF patients with LVEF &le;35 percent discharged alive between January 2005 to June 2007, less than 40 percent of patients received ICD therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?14/62/15338/abstract/42\">",
"       42",
"      </a>",
"      ]. The rates of use were lower among women and black patients as compared to white men. The impact of these differences on clinical outcomes was not assessed.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The utilization of ICD therapies can vary markedly depending on how the device is programmed. For decades, the optimal ICD programming to deliver antitachycardia ICD therapies, either pacing or shocks, was thought to involve delivering therapy with the minimal possible delay and for any ventricular arrhythmia that is present and sustained until therapy delivery. However, the exact circumstances in which to institute therapy for a tachyarrhythmia in patients with an ICD were not known. In MADIT-RIT, a randomized trial of three different ICD programming and therapy strategies in 1500 patients receiving an ICD for primary prevention, both therapy utilization and overall mortality were lower in persons programmed with longer delays prior to therapy and in those programmed to receive therapies only at higher heart rates [",
"    <a class=\"abstract\" href=\"UTD.htm?14/62/15338/abstract/44\">",
"     44",
"    </a>",
"    ]. ICD programming strategies are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/50/24362?source=see_link&amp;anchor=H9233111#H9233111\">",
"     \"General principles of the implantable cardioverter-defibrillator\", section on 'Optimal ICD programming'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     ANTIARRHYTHMIC DRUGS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antiarrhythmic drugs, including",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/13/21721?source=see_link\">",
"     sotalol",
"    </a>",
"    , have been evaluated for the primary prevention of SCD. For most post-MI patients, there is no evidence of a significant survival benefit, although amiodarone may reduce arrhythmic death in selected subgroups [",
"    <a class=\"abstract\" href=\"UTD.htm?14/62/15338/abstract/45,46\">",
"     45,46",
"    </a>",
"    ]. Class IC antiarrhythmic drugs (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/30/30182?source=see_link\">",
"     flecainide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/51/26423?source=see_link\">",
"     propafenone",
"    </a>",
"    ) should be",
"    <strong>",
"     avoided",
"    </strong>",
"    in patients with coronary artery disease, because they increase mortality due to their proarrhythmic effect [",
"    <a class=\"abstract\" href=\"UTD.htm?14/62/15338/abstract/47\">",
"     47",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/53/16217?source=see_link\">",
"     \"Role of antiarrhythmic drugs for ventricular arrhythmias in patients with a prior myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Primary therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;All currently available antiarrhythmic drugs have limited efficacy in the primary prevention of SCD and also have a proarrhythmic potential. Given the established superiority of an ICD in high-risk patients (as in SCD-HeFT [",
"    <a class=\"abstract\" href=\"UTD.htm?14/62/15338/abstract/26\">",
"     26",
"    </a>",
"    ]), antiarrhythmic drugs for the primary prevention of SCD are only considered in selected cases in which a patient is not a candidate for an ICD.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Adjunctive therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients who already have an ICD in place, but have frequent ICD shocks due to recurrent arrhythmias, antiarrhythmic therapy, usually",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    , may be used to reduce the frequency of shocks. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/23/43385?source=see_link&amp;anchor=H13#H13\">",
"     \"Role of implantable cardioverter-defibrillators for the secondary prevention of sudden cardiac death\", section on 'Antiarrhythmic drugs'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?37/60/38850?source=see_link\">",
"       \"Patient information: Implantable cardioverter-defibrillators (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topic (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?11/20/11589?source=see_link\">",
"       \"Patient information: Implantable cardioverter-defibrillators (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal approach to the prevention of SCD in post-MI patients remains incompletely defined. The general strategy includes the following components:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Standard medical therapies.",
"     </li>",
"     <li>",
"      Identification of those patients at greatest risk for malignant arrhythmias [",
"      <a class=\"abstract\" href=\"UTD.htm?14/62/15338/abstract/4,5\">",
"       4,5",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/24/20874?source=see_link\">",
"       \"Incidence of and risk stratification for sudden cardiac death after acute myocardial infarction\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      ICD placement in selected high-risk patients.",
"     </li>",
"     <li>",
"      Antiarrhythmic drugs in special circumstances, usually as adjunctive therapy in patients with an ICD who experience frequent shocks, or less commonly, as primary therapy in patients who are not candidates for an ICD. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/53/16217?source=see_link\">",
"       \"Role of antiarrhythmic drugs for ventricular arrhythmias in patients with a prior myocardial infarction\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Standard medical therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;As outlined above, many components of the standard medical regimen for patients with coronary artery disease and a prior myocardial infarction appear to reduce SCD [",
"    <a class=\"abstract\" href=\"UTD.htm?14/62/15338/abstract/6-12,14\">",
"     6-12,14",
"    </a>",
"    ]. Most patients should be on a regimen that includes:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Beta blocker",
"     </li>",
"     <li>",
"      ACE inhibitor or an ARB",
"     </li>",
"     <li>",
"      A statin",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, in selected patients with persistent HF, an aldosterone antagonist may be added. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Medical therapy'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Risk stratification",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although there are extensive data regarding the significance of a number of risk factors, the findings that have the most clinical impact are those that determine whether or not a patient will require an ICD. Recommendations for risk stratification are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/24/20874?source=see_link&amp;anchor=H22#H22\">",
"     \"Incidence of and risk stratification for sudden cardiac death after acute myocardial infarction\", section on 'Summary and recommendations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with sustained VT or VF after the acute phase of an MI (ie, after 24 to 48 hours) generally receive an ICD for secondary prevention. The management of these patients is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/10/30890?source=see_link&amp;anchor=H38#H38\">",
"     \"Clinical features and treatment of ventricular arrhythmias during acute myocardial infarction\", section on 'Late arrhythmias'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/32/29193?source=see_link\">",
"     \"Sustained monomorphic ventricular tachycardia in patients with a prior myocardial infarction: Treatment and prognosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/23/43385?source=see_link\">",
"     \"Role of implantable cardioverter-defibrillators for the secondary prevention of sudden cardiac death\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     ICD therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recommendations for selecting post-MI patients for ICD therapy are largely based upon the entry criteria in the major trials.",
"   </p>",
"   <p>",
"    The following criteria apply to patients who are more than 40 days post MI and more than three months post PCI or CABG (see",
"    <a class=\"local\" href=\"#H17\">",
"     'ACC/AHA/ESC and ACC/AHA/HRS guidelines'",
"    </a>",
"    above):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We recommend that patients who meet MADIT II criteria (prior MI with an LVEF &le;30 percent) be treated with an ICD (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). A negative EP study performed in the past should not preclude ICD implantation.",
"     </li>",
"     <li>",
"      We recommend that patients who satisfy SCD-HEFT criteria (LVEF &le;35 percent and NYHA II or III HF) be treated with an ICD (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). A negative EP study should not preclude ICD implantation.",
"     </li>",
"     <li>",
"      For patients with a prior MI and an LVEF &le;40 percent who do not meet the above criteria, we recommend periodic Holter monitoring, and patients found to have NSVT should be referred for EP study, as in MUSTT and MADIT I. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'MUSTT and MADIT trials'",
"      </a>",
"      above.) If the EP study is positive, we recommend ICD implantation (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Some experts recommend ICD implantation in selected patients who do not meet inclusion criteria in the major clinical trials cited above, particularly if additional risk factors (eg, NSVT, abnormal SAECG, or abnormal TWA) are present. These suggestions are consistent with the known risk of SCD in these populations and the established efficacy of the ICD in other high-risk cohorts. Although some patients and clinicians may prefer this more aggressive approach, the benefit of ICD therapy in such patients is not proven.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We recommend that patients with an indication for CRT, currently defined as an LVEF &le;35 percent, LV dyssynchrony (QRS &gt;120 msec), and moderate to severe symptoms (NYHA class III or ambulatory class IV HF) despite optimal medical therapy, should be treated with a combined",
"      <span class=\"nowrap\">",
"       ICD/CRT",
"      </span>",
"      device (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?14/62/15338/abstract/48\">",
"       48",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Cardiac resynchronization'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In patients who meet any of the above criteria but are within 40 days of an MI or within three months of CABG or PCI, care must be individualized. Some patients will recover some LV function and therefore not \"qualify\" for prophylactic ICD implantation [",
"    <a class=\"abstract\" href=\"UTD.htm?14/62/15338/abstract/49,50\">",
"     49,50",
"    </a>",
"    ]. However, because improvement in LV function is only one of several possible explanations for the lack of benefit seen in DINAMIT and IRIS, the long-term risk profile of such patients is not known.",
"   </p>",
"   <p>",
"    Waiting one month after MI before considering ICD implantation may expose some patients, especially those with a large MI, to significant risk. In such patients, it may be reasonable to consider use of an ambulatory defibrillator vest. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/50/24362?source=see_link&amp;anchor=H29#H29\">",
"     \"General principles of the implantable cardioverter-defibrillator\", section on 'Wearable cardioverter-defibrillator'",
"    </a>",
"    .)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/62/15338/abstract/1\">",
"      Marchioli R, Barzi F, Bomba E, et al. Early protection against sudden death by n-3 polyunsaturated fatty acids after myocardial infarction: time-course analysis of the results of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI)-Prevenzione. Circulation 2002; 105:1897.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/62/15338/abstract/2\">",
"      Solomon SD, Zelenkofske S, McMurray JJ, et al. Sudden death in patients with myocardial infarction and left ventricular dysfunction, heart failure, or both. N Engl J Med 2005; 352:2581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/62/15338/abstract/3\">",
"      Berger CJ, Murabito JM, Evans JC, et al. Prognosis after first myocardial infarction. Comparison of Q-wave and non-Q-wave myocardial infarction in the Framingham Heart Study. JAMA 1992; 268:1545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/62/15338/abstract/4\">",
"      Bailey JJ, Berson AS, Handelsman H, Hodges M. Utility of current risk stratification tests for predicting major arrhythmic events after myocardial infarction. J Am Coll Cardiol 2001; 38:1902.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/62/15338/abstract/5\">",
"      Reynolds MR, Josephson ME. MADIT II (second Multicenter Automated Defibrillator Implantation Trial) debate: risk stratification, costs, and public policy. Circulation 2003; 108:1779.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/62/15338/abstract/6\">",
"      Nuttall SL, Toescu V, Kendall MJ. beta Blockade after myocardial infarction. Beta blockers have key role in reducing morbidity and mortality after infarction. BMJ 2000; 320:581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/62/15338/abstract/7\">",
"      Friedman LM, Byington RP, Capone RJ, et al. Effect of propranolol in patients with myocardial infarction and ventricular arrhythmia. J Am Coll Cardiol 1986; 7:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/62/15338/abstract/8\">",
"      Brodine WN, Tung RT, Lee JK, et al. Effects of beta-blockers on implantable cardioverter defibrillator therapy and survival in the patients with ischemic cardiomyopathy (from the Multicenter Automatic Defibrillator Implantation Trial-II). Am J Cardiol 2005; 96:691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/62/15338/abstract/9\">",
"      Domanski MJ, Exner DV, Borkowf CB, et al. Effect of angiotensin converting enzyme inhibition on sudden cardiac death in patients following acute myocardial infarction. A meta-analysis of randomized clinical trials. J Am Coll Cardiol 1999; 33:598.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/62/15338/abstract/10\">",
"      Pfeffer MA, McMurray JJ, Velazquez EJ, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003; 349:1893.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/62/15338/abstract/11\">",
"      Mitchell LB, Powell JL, Gillis AM, et al. Are lipid-lowering drugs also antiarrhythmic drugs? An analysis of the Antiarrhythmics versus Implantable Defibrillators (AVID) trial. J Am Coll Cardiol 2003; 42:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/62/15338/abstract/12\">",
"      Chiu JH, Abdelhadi RH, Chung MK, et al. Effect of statin therapy on risk of ventricular arrhythmia among patients with coronary artery disease and an implantable cardioverter-defibrillator. Am J Cardiol 2005; 95:490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/62/15338/abstract/13\">",
"      Dickinson MG, Ip JH, Olshansky B, et al. Statin use was associated with reduced mortality in both ischemic and nonischemic cardiomyopathy and in patients with implantable defibrillators: mortality data and mechanistic insights from the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT). Am Heart J 2007; 153:573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/62/15338/abstract/14\">",
"      Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003; 348:1309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/62/15338/abstract/15\">",
"      Albert CM, Hennekens CH, O'Donnell CJ, et al. Fish consumption and risk of sudden cardiac death. JAMA 1998; 279:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/62/15338/abstract/16\">",
"      Siscovick DS, Raghunathan TE, King I, et al. Dietary intake and cell membrane levels of long-chain n-3 polyunsaturated fatty acids and the risk of primary cardiac arrest. JAMA 1995; 274:1363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/62/15338/abstract/17\">",
"      Bilchick KC, Stukenborg GJ, Kamath S, Cheng A. Prediction of mortality in clinical practice for medicare patients undergoing defibrillator implantation for primary prevention of sudden cardiac death. J Am Coll Cardiol 2012; 60:1647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/62/15338/abstract/18\">",
"      Goldberger Z, Lampert R. Implantable cardioverter-defibrillators: expanding indications and technologies. JAMA 2006; 295:809.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/62/15338/abstract/19\">",
"      Wilber DJ, Zareba W, Hall WJ, et al. Time dependence of mortality risk and defibrillator benefit after myocardial infarction. Circulation 2004; 109:1082.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/62/15338/abstract/20\">",
"      Goldenberg I, Moss AJ, McNitt S, et al. Time dependence of defibrillator benefit after coronary revascularization in the Multicenter Automatic Defibrillator Implantation Trial (MADIT)-II. J Am Coll Cardiol 2006; 47:1811.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/62/15338/abstract/21\">",
"      Goldenberg I, Moss AJ, McNitt S, et al. Relations among renal function, risk of sudden cardiac death, and benefit of the implanted cardiac defibrillator in patients with ischemic left ventricular dysfunction. Am J Cardiol 2006; 98:485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/62/15338/abstract/22\">",
"      Koplan BA, Epstein LM, Albert CM, Stevenson WG. Survival in octogenarians receiving implantable defibrillators. Am Heart J 2006; 152:714.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/62/15338/abstract/23\">",
"      Buxton AE, Lee KL, Fisher JD, et al. A randomized study of the prevention of sudden death in patients with coronary artery disease. Multicenter Unsustained Tachycardia Trial Investigators. N Engl J Med 1999; 341:1882.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/62/15338/abstract/24\">",
"      Moss AJ, Hall WJ, Cannom DS, et al. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter Automatic Defibrillator Implantation Trial Investigators. N Engl J Med 1996; 335:1933.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/62/15338/abstract/25\">",
"      Moss AJ, Zareba W, Hall WJ, et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 2002; 346:877.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/62/15338/abstract/26\">",
"      Bardy GH, Lee KL, Mark DB, et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 2005; 352:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/62/15338/abstract/27\">",
"      Chan PS, Chow T, Kereiakes D, et al. Effectiveness of implantable cardioverter-defibrillators in patients with ischemic heart disease and left ventricular dysfunction. Arch Intern Med 2006; 166:2228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/62/15338/abstract/28\">",
"      Greenberg H, Case RB, Moss AJ, et al. Analysis of mortality events in the Multicenter Automatic Defibrillator Implantation Trial (MADIT-II). J Am Coll Cardiol 2004; 43:1459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/62/15338/abstract/29\">",
"      Ezekowitz JA, Armstrong PW, McAlister FA. Implantable cardioverter defibrillators in primary and secondary prevention: a systematic review of randomized, controlled trials. Ann Intern Med 2003; 138:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/62/15338/abstract/30\">",
"      Hohnloser SH, Kuck KH, Dorian P, et al. Prophylactic use of an implantable cardioverter-defibrillator after acute myocardial infarction. N Engl J Med 2004; 351:2481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/62/15338/abstract/31\">",
"      Steinbeck G, Andresen D, Seidl K, et al. Defibrillator implantation early after myocardial infarction. N Engl J Med 2009; 361:1427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/62/15338/abstract/32\">",
"      Gillis AM. Prophylactic implantable cardioverter-defibrillators after myocardial infarction--not for everyone. N Engl J Med 2004; 351:2540.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/62/15338/abstract/33\">",
"      Bristow MR, Saxon LA, Boehmer J, et al. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med 2004; 350:2140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/62/15338/abstract/34\">",
"      European Heart Rhythm Association, Heart Rhythm Society, Zipes DP, et al. ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death). J Am Coll Cardiol 2006; 48:e247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/62/15338/abstract/35\">",
"      Epstein AE, DiMarco JP, Ellenbogen KA, et al. ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices): developed in collaboration with the American Association for Thoracic Surgery and Society of Thoracic Surgeons. Circulation 2008; 117:e350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/62/15338/abstract/36\">",
"      Buxton AE. The clinical use of implantable cardioverter defibrillators: where are we now? Where should we go? Ann Intern Med 2003; 138:512.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/62/15338/abstract/37\">",
"      Buxton AE. Should everyone with an ejection fraction less than or equal to 30% receive an implantable cardioverter-defibrillator? Not everyone with an ejection fraction &lt; or = 30% should receive an implantable cardioverter-defibrillator. Circulation 2005; 111:2537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/62/15338/abstract/38\">",
"      Moss AJ. Should everyone with an ejection fraction less than or equal to 30% receive an implantable cardioverter-defibrillator? Everyone with an ejection fraction &lt; or = 30% should receive an implantable cardioverter-defibrillator. Circulation 2005; 111:2537.",
"     </a>",
"    </li>",
"    <li>",
"     Centers for Medicare and Medicaid Services. Summary of coverage for implantable cardioverter defibrillators (ICDs) as of January 27, 2005 www.cms.hhs.gov/mcd/viewimplementation.asp?id=148 (Accessed on September 20, 2006).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/62/15338/abstract/40\">",
"      McClellan MB, Tunis SR. Medicare coverage of ICDs. N Engl J Med 2005; 352:222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/62/15338/abstract/41\">",
"      Curtis LH, Al-Khatib SM, Shea AM, et al. Sex differences in the use of implantable cardioverter-defibrillators for primary and secondary prevention of sudden cardiac death. JAMA 2007; 298:1517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/62/15338/abstract/42\">",
"      Hernandez AF, Fonarow GC, Liang L, et al. Sex and racial differences in the use of implantable cardioverter-defibrillators among patients hospitalized with heart failure. JAMA 2007; 298:1525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/62/15338/abstract/43\">",
"      Redberg RF. Disparities in use of implantable cardioverter-defibrillators: moving beyond process measures to outcomes data. JAMA 2007; 298:1564.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/62/15338/abstract/44\">",
"      Moss AJ, Schuger C, Beck CA, et al. Reduction in inappropriate therapy and mortality through ICD programming. N Engl J Med 2012; 367:2275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/62/15338/abstract/45\">",
"      Cairns JA, Connolly SJ, Roberts R, Gent M. Randomised trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarisations: CAMIAT. Canadian Amiodarone Myocardial Infarction Arrhythmia Trial Investigators. Lancet 1997; 349:675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/62/15338/abstract/46\">",
"      Julian DG, Camm AJ, Frangin G, et al. Randomised trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction: EMIAT. European Myocardial Infarct Amiodarone Trial Investigators. Lancet 1997; 349:667.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/62/15338/abstract/47\">",
"      Echt DS, Liebson PR, Mitchell LB, et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N Engl J Med 1991; 324:781.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/62/15338/abstract/48\">",
"      Hunt SA, Abraham WT, Chin MH, et al. 2009 focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 2009; 119:e391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/62/15338/abstract/49\">",
"      Sheehan FH, Doerr R, Schmidt WG, et al. Early recovery of left ventricular function after thrombolytic therapy for acute myocardial infarction: an important determinant of survival. J Am Coll Cardiol 1988; 12:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/62/15338/abstract/50\">",
"      Solomon SD, Glynn RJ, Greaves S, et al. Recovery of ventricular function after myocardial infarction in the reperfusion era: the healing and early afterload reducing therapy study. Ann Intern Med 2001; 134:451.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1047 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-41.78.124.10-AD1D6AEAC5-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_62_15338=[""].join("\n");
var outline_f14_62_15338=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H26\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      MEDICAL THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      RISK STRATIFICATION STRATEGIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      High-risk patients",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Identification of low-risk patients",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Timing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Impact of age and comorbidities",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      ICD TRIALS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      MUSTT and MADIT trials",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Summary",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Trials early post MI",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - DINAMIT trial",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - IRIS trial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      SCD-HeFT trial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      COMPANION trial",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      EVOLVING INDICATIONS FOR AN ICD FOLLOWING MYOCARDIAL INFARCTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      ACC/AHA/ESC and ACC/AHA/HRS guidelines",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - General ICD indications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Cardiac resynchronization",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Center for Medicare Services",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      UTILIZATION AND OUTCOMES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      ANTIARRHYTHMIC DRUGS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Primary therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Adjunctive therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Standard medical therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Risk stratification",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      ICD therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/1047\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1047|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?1/34/1582\" title=\"figure 1\">",
"      ICD vs no ICD MUSTT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?38/48/39693\" title=\"figure 2\">",
"      ICD in NSVT in MADIT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?19/35/20029\" title=\"figure 3\">",
"      ICD low EF post MI MADIT II",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1047|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?3/2/3117\" title=\"table 1\">",
"      Methods to assess cardiovascular disability",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/30/26088?source=related_link\">",
"      Angiotensin converting enzyme inhibitors and receptor blockers in acute myocardial infarction: Clinical trials",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/55/13175?source=related_link\">",
"      Angiotensin converting enzyme inhibitors and receptor blockers in acute myocardial infarction: Recommendations for use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/53/11098?source=related_link\">",
"      Beta blockers in the management of acute coronary syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/56/18314?source=related_link\">",
"      Cardiac resynchronization therapy in heart failure: Indications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/55/33656?source=related_link\">",
"      Cholesterol lowering after an acute coronary syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/10/30890?source=related_link\">",
"      Clinical features and treatment of ventricular arrhythmias during acute myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/50/24362?source=related_link\">",
"      General principles of the implantable cardioverter-defibrillator",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/12/19657?source=related_link\">",
"      Implantable cardioverter-defibrillators: Clinical trials of primary prevention of sudden cardiac death",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/24/20874?source=related_link\">",
"      Incidence of and risk stratification for sudden cardiac death after acute myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/55/890?source=related_link\">",
"      Overview of sudden cardiac arrest and sudden cardiac death",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/41/44697?source=related_link\">",
"      Overview of the acute management of ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/20/37193?source=related_link\">",
"      Overview of the acute management of unstable angina and non-ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?11/20/11589?source=related_link\">",
"      Patient information: Implantable cardioverter-defibrillators (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?37/60/38850?source=related_link\">",
"      Patient information: Implantable cardioverter-defibrillators (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/23/3448?source=related_link\">",
"      Pharmacologic therapy in survivors of sudden cardiac arrest",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/43/2746?source=related_link\">",
"      Risk stratification after unstable angina or non-ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/52/35658?source=related_link\">",
"      Risk stratification for cardiac events after acute ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/53/16217?source=related_link\">",
"      Role of antiarrhythmic drugs for ventricular arrhythmias in patients with a prior myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/23/43385?source=related_link\">",
"      Role of implantable cardioverter-defibrillators for the secondary prevention of sudden cardiac death",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/55/19322?source=related_link\">",
"      Secondary and primary prevention of sudden cardiac death in heart failure and cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/32/29193?source=related_link\">",
"      Sustained monomorphic ventricular tachycardia in patients with a prior myocardial infarction: Treatment and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/48/5898?source=related_link\">",
"      T wave (repolarization) alternans: Clinical aspects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/54/28521?source=related_link\">",
"      Use of aldosterone antagonists in heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/47/21241?source=related_link\">",
"      Ventricular arrhythmias in heart failure and cardiomyopathy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_62_15339="Drugs prevention osteoporosis";
var content_f14_62_15339=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F64685&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F64685&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Available FDA-approved medications for the prevention of osteoporosis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Drug class",
"       </td>",
"       <td class=\"subtitle1\">",
"        Medication",
"       </td>",
"       <td class=\"subtitle1\">",
"        Dose",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Estrogens",
"       </td>",
"       <td>",
"        Many",
"       </td>",
"       <td>",
"        Variable",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"4\">",
"        Bisphosphonates",
"       </td>",
"       <td>",
"        Alendronate",
"       </td>",
"       <td>",
"        35 mg/week or 5 mg/day",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Risedronate",
"       </td>",
"       <td>",
"        35 mg/week or 5 mg/day",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ibandronate",
"       </td>",
"       <td>",
"        150 mg/month",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Zoledronic acid",
"       </td>",
"       <td>",
"        5 mg IV once every two years",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Selective estrogen receptor modulator (SERM)",
"       </td>",
"       <td>",
"        Raloxifene",
"       </td>",
"       <td>",
"        60 mg/day",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     IV: intravenous.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_62_15339=[""].join("\n");
var outline_f14_62_15339=null;
var title_f14_62_15340="Infectious mimics of IBD";
var content_f14_62_15340=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F67648&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F67648&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Infectious mimics of inflammatory bowel disease",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Infectious agents causing colitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Bacteria",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Shigella species",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Enterohemorrhagic Escherichia coli",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Enteroinvasive Escherichia coli",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Campylobacter jejuni",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Salmonella species (gastroenteritis and typhoid fever)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Yersinia enterocolitica",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Mycobacterium tuberculosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Clostridium difficile",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Vibrio parahaemolyticus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Chlamydia trachomatis (lymphogranuloma venereum serotypes)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Parasites",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Entamoeba histolytica",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Schistosoma species",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Balantidium coli",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Trichinella spiralis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Viruses",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Cytomegalovirus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Infectious agents causing proctitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Neisseria gonorrhoeae",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Herpes simplex virus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chlamydia trachomatis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Treponema pallidum",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cytomegalovirus",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Guerrant RL, Lima AA. Inflammtory enteritides. In: Principles and Practice of Infectious Diseases, 5th ed, Mandell GL, Bennett JE, Dolin R (Eds), Churchill Livingstone, Philadelphia 2000. p.1127.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_62_15340=[""].join("\n");
var outline_f14_62_15340=null;
var title_f14_62_15341="Features of drug induced LE";
var content_f14_62_15341=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F69467&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F69467&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Features of spontaneous and drug-induced lupus",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Clinical feature",
"       </td>",
"       <td class=\"subtitle1\">",
"        Spontaneous lupus",
"       </td>",
"       <td class=\"subtitle1\">",
"        Drug-induced lupus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Usual age",
"       </td>",
"       <td>",
"        20-40",
"       </td>",
"       <td>",
"        50",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Female to male ratio",
"       </td>",
"       <td>",
"        9:1",
"       </td>",
"       <td>",
"        1:1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Race",
"       </td>",
"       <td>",
"        All",
"       </td>",
"       <td>",
"        \"No blacks\"",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Acetylation type",
"       </td>",
"       <td>",
"        Slow = Fast",
"       </td>",
"       <td>",
"        Slow",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Onset of symptoms",
"       </td>",
"       <td>",
"        Gradual",
"       </td>",
"       <td>",
"        Abrupt",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Constitutional symptoms",
"       </td>",
"       <td>",
"        83",
"       </td>",
"       <td>",
"        50",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Arthralgia and arthritis",
"       </td>",
"       <td>",
"        90",
"       </td>",
"       <td>",
"        95",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pleuropericarditis (procainamide)",
"       </td>",
"       <td>",
"        50",
"       </td>",
"       <td>",
"        50",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hepatomegaly",
"       </td>",
"       <td>",
"        25",
"       </td>",
"       <td>",
"        25",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Rash (all types)",
"       </td>",
"       <td class=\"sublist_other_start\">",
"        74",
"       </td>",
"       <td class=\"sublist_other_start\">",
"        10-20",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Discoid lesions",
"       </td>",
"       <td class=\"sublist_other\">",
"        20",
"       </td>",
"       <td class=\"sublist_other\">",
"        0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Malar erythema",
"       </td>",
"       <td class=\"sublist_other\">",
"        42",
"       </td>",
"       <td class=\"sublist_other\">",
"        2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Renal disease",
"       </td>",
"       <td>",
"        53",
"       </td>",
"       <td>",
"        5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        CNS disease",
"       </td>",
"       <td>",
"        32",
"       </td>",
"       <td>",
"        0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hematologic abnormalities",
"       </td>",
"       <td>",
"        Common",
"       </td>",
"       <td>",
"        Unusual",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"3\">",
"        Immunologic abnormalities",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        ANA",
"       </td>",
"       <td class=\"sublist_other\">",
"        95",
"       </td>",
"       <td class=\"sublist_other\">",
"        95",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        LE cells",
"       </td>",
"       <td class=\"sublist_other\">",
"        90",
"       </td>",
"       <td class=\"sublist_other\">",
"        90",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Anti-RNP",
"       </td>",
"       <td class=\"sublist_other\">",
"        40-50",
"       </td>",
"       <td class=\"sublist_other\">",
"        20",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Anti-Sm (Smith)",
"       </td>",
"       <td class=\"sublist_other\">",
"        20-30",
"       </td>",
"       <td class=\"sublist_other\">",
"        Rare",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Anti-dsDNA",
"       </td>",
"       <td class=\"sublist_other\">",
"        80",
"       </td>",
"       <td class=\"sublist_other\">",
"        Rare",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Anti-histone*",
"       </td>",
"       <td class=\"sublist_other\">",
"        60-80",
"       </td>",
"       <td class=\"sublist_other\">",
"        90-95",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Complement",
"       </td>",
"       <td class=\"sublist_other\">",
"        Reduced",
"       </td>",
"       <td class=\"sublist_other\">",
"        Normal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Immune complexes",
"       </td>",
"       <td class=\"sublist_other\">",
"        Elevated",
"       </td>",
"       <td class=\"sublist_other\">",
"        Normal",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     CNS: central nervous system; ANA: anti-nuclear antibody; LE: lupus erythematosus; RNP: ribonucleoprotein; Sm: Smith; dsDNA: double-stranded deoxyribonucleic acid.",
"     <br>",
"      * Overall presence of anti-histone antibodies in drug-induced lupus; prevalence varies markedly between implicated drugs. (Merola JF. Lupus-like syndromes related to drugs. In: Lupus Erythematosus: Clinical Evaluation and Treatment, Schur PH, Massarotti E. (Eds), Springer, New York. in press.)",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_62_15341=[""].join("\n");
var outline_f14_62_15341=null;
var title_f14_62_15342="ECG gated MPI and outcomes";
var content_f14_62_15342=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F72140&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F72140&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 628px\">",
"   <div class=\"ttl\">",
"    Wall motion and left ventricular fraction scores",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 608px; height: 240px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Travin MI, Heller GV, Johnson LL, et al. The prognostic value of ECG-gated SPECT imaging in patients undergoing stress Tc-99m sestamibi myocardial perfusion imaging. J Nucl Cardiol 2004; 11:253. Copyright &copy; 2004 The American Society of Nuclear Cardiology.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_62_15342=[""].join("\n");
var outline_f14_62_15342=null;
var title_f14_62_15343="Metabolism of glucose";
var content_f14_62_15343=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F76153&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F76153&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 563px\">",
"   <div class=\"ttl\">",
"    Metabolism of glucose",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 543px; height: 438px; background-image: url(data:image/gif;base64,R0lGODlhHwK2AfcAAP///wAz/5kzAAAAAP8AAICAgAAZf39/f0BAQL+/vz8/Pw8PD8DAwF9fXx8fH+/v78/Pz9/f3y8vL5+fnz9m/6+vr7/M/1BQUO/y/29vbyAgIE9PT4+Pj3ImABAQEPDw8KCgoF9//7CwsHBwcODg4H+Z/9/l/0wZAA8//zAwMC9Z/2BgYNDQ0K+////AwP8gIJ+y//9gYJCQkB9M//+goI+l/xwJAP+AgG+M/48vAE9y/yYMAM/Y//9AQIUsADkTAF8fAC8PAAkDAFYcAP+fnxMGAP8QEP8fHwAMP3wpAP9fX//w8EIWAP+wsP8wMGkjAAAmv//g4P9QUP+/vwATX/+QkAAGHwAWbwAjr/8PDwAcjz8AAAAJLwApz/9/f18fn/+vr18AAAADD58TX78MP38Zf58AAP8vLwAPTwAv7//Q0P9PT98AAP8/Pz8mv//f398GH68PT28AAK+8788AAL8AAH8pj38AAP9wcC9Mv//v788JL08jr68AAH9Zvw8AAH+Mvx8sX+8DD/9vbw8v7wAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAACH5BAAAAAAALAAAAAAfArYBAAj/AAEIHEiwoMGDCBMqXMiwocOHECNKnEixosWLGDNq3Mixo8ePIEOKHEmypMmTKFOqXMmypcuXMGPKnEmzps2bOHPq3Mmzp8+fQIMKHUq0qNGjSJMqXcq0qdOnUKNKnUq1qtWrWLNq3cq1q9evYMOKHUu2rNmzaNOqXcu2rdu3cOPKnUu3rt27ePPq3cu3r9+/gAMLHky4sOHDiBMrXsy4sePHkCNLnky5suXLmDNrtssCAYjNoEMjZTCggOjTqHOyuHChQAESpE2DMA1gtkAQFxCM+ABABoILIgSyWPH784cCv4OnXs7cIQkPHpAPYBAbAIIBAq8DKDCgtQYGIwaM/7gwQASJASkKrLgAIEX0FANYNJ9PvyD3z9ypl7aOnT8ADxoI9MEHHqQAwAfdsTCABiPI8IGCCKi3X30UNpffdtNVp51/AyBAUIcCgSgCAh6gR1qErjFQ4YqpidAdA9fpZxp5F4xQIgDkycDABTuWx52OK4jAAHT/eQACAzJ8xuKSoYVXYIb7saBBd/AduEKJGpDwAXkejAAACfChJ99qAyyoHJNoYqajCPDxluabcCI0JXpnxmnnnXjmqeeefPbp55+ABirooIQWauihiCaq6KKMNuroo5BGKumklFZqKVEa1HnppnCViQAJnIbqVpllFuCmqKiaRWqZmabq6lirkv/66au0EhXrrbjmmquptfbqk67ABkuqBkr6aqxUtxJ77LLIDlsss9A2xeqz0VarlLLWSgqbfACwoKKA1A30AXUMcCtQuF8yAKpMIAR4UmfUvjSChwTNG5G365Y70Lb7krvuQDBmG1N1Dh15EHfx+SdQeOWdu6oG3JYpEHe0vcRAmCgRzBCICG14kW0EeWzfvyEvyBvH7ZXpJsKenhqwwAiRUIAI8wYnwmu1mTobCTKQAPJsx30mc3DzIrCCfCt0aNpxyXVcMUEIe+jxnCs47OGQHpzcH8UvdbZqxvvtiAACMghEwrzAgbDga2KTDQADUxagoti7EUQCcbq5iVveII//eMGUCE130HX7cXxemUpyLQOIpMkKs0GkaVAAfCyoXTaA/JUIY3/aaeBBbwN8JrmNAcKngYfuTZ6wQREe3OEAvvXnogwl8naiQEmXXap0T6d0961gm6aedCAQGB1xTiLAwvDXgQBCiZ65WGN3BMEoYdXcebc5AC6mB/hBgrP+OoQLh47exBNOye3LjxdUnYumFjg7f25uqB13IlyQ9dvz3lgdhBJ6WuO+BrXpeK5KAEja7z5zOwyZ5la9M8lxchW8A8ngAvApwOKUBCqOfeCCGVQYeVzzvYGAgDggwtyBPqAd8oBKZBhaFb0Gcp3zXIdeGgjQlEDFNf58i33tA1jY//aTtDYpTGHaOU/SqiY9NmGnOidyjdwIMq6LrQBdA8nPAA/kqSkZqIFJ+4zEHKiSApRIWGjEFUSq4x4ZLM414QsRvdr4RiSWRor1Es/tUOYf+/WnX6TRkbmyg52ocW8AHiCReMgIgB0GMSGkuSLl3lYm9hyRRjbqT5hURDERAI40wCnSkZI0uAhiSEWEA90KXFMib5mIOwYCwBh7iBIzpvGWBHRIdRYEntIoKAUMwI0sv3Oe74THNNcRAQsWxyMRVI2G5VGbh3K0o+11soQFiWPJDgQ9HN3RSRi6Inm89EiERA6RxZqScjwmJSr1R23u+oDpvnedz5HJTAcZQbxO+f8liRkRAOEZwQA9sAI3zXJCKfkAw4B3kuqo7XWmceJ+EFY5T+1HBCUqWwHmZEnhQA9EH7jSgkigHRYuCJshGyQ0b9MhBMUyZTcblinL6bDeIchdgvldrGh6GY0JpI6F2RypBmKEGyyBp0iFCdzGCAACEKCoR02qVFfSroE49aoxiMJUt7qSq3o1q1wNa0m8StYeuECsaP0IWddq1rQKzAU36IFTCUJWunrVrlfF61wFsta+voAGbp1UDPRKAMIadiAvuKtVFctXxjaVsX2N7F8DO6i6LjaviHWsXDErkM3uVSBScKxlG8vZx3I2sn0tKmXzNFoAJLa0ni3sQEJb2hv/ONa2tRWtbks7WtR6FaqrZVJrX/tZANC2uLhFrmNdsNzm8na3xe2tbwkQg6gGty9MHUkTYmCEswqEuLIF7W2dW1zmlrYmvgXrdf+SXZCQ9QazHW9pzVvco0S2B1pdL2Dae5HtGoEA3gVAbHswkOSGFwDM7cENAhwVtjJYv37hr0W8Cl+BGDi8CV5wV7zqhAdDOMJ/jAgNEstgzxJYIPSlblmcOtkPD0bCDInBVStsYceqpcUufnGIH+LVE6PYCDFogodzHEQYLyS2RE6rkQciY8AW2MZJnuqSASBjAryAIC74qwuGHGWkLtkJXnVylym7ZDV49cpjJvOODZLcwaY5/7DtjYET8iuQGGz5zWomCA2caoQmEMS6eFZyiMGLh0Bfl6lVZrGYDQ3nP46YxYw+9I5HvOhIu3XKlr70mjMd3DJZudKcbvRVcRzqS4fhzKUmMxvCnGo4f7XVcN5CXA8Ma7EyFdC15iqmc+3lTWulqrzWDAHoEIMqcJkqF9t1sBvTWqt4bahNsddB4JUR3RRE2svWSLMbSi4GfAA25OJWFTei01wKhY8mnKlPK1IAasEw2xOGsklixQCWcYxhmprIBNU4FHi+Zmc9A9lqWsM2X06x3vJhAHGO9rbc1A3gMlOS375HN94odGwzhXdBtj3vDHmbO1fUVyPL9Ex2nxGXKP9PebAakjyvaS6J0JGOjM7DHheSJj0Rkl542FPP6YgIPRvFjs6p57kCjACnGk+IskOyO+EpbYqzq51F2qXyqlvd3Arh2HXqV8jQnVJDA6C5N9dFghEGnX5yHLt/zA446KySZEkHn69PslN7m0aBYcQICAi3U1vRy2P3E5wW96M2+ARHZNeRIjL/CCI/8kfx3fobIuEe9w/NveMFrBiCOuRFjfQI60DhJUn/qB3pbU5G3ETkTwdwRdcwkwHOPCKIromd18feM5tTaeUHsnSQZJeWi1ulLXVfkXIXhaKA74+T4IP6BC5yYlPyQHCCTj2PgfQ6OdwaR725oH3uXpayluv/sUXye4T+M6AdOc7norKmfw4EPpT//koGQGE4zSkFmiKf/GFC/6v6eP8w03/nBYDWMgBmQAAKNn4EeCy9t4C90oAOSCsQGIGuMoEUiCoSA1dy5WcXyCwS82qAAlwdSH7YcVxGECh8ZlQj6HvYsWcDuCdkpV4ruBESswQIqGGA0lcyOIMXYYEs6Bio1VY8aBE++BFFiBfTJYRDKBFH2BFNuBQaSGs2NoXnBVnT9WlLGBH8NWIcmBJPOBMMRoX1JYZSWIVm+FlXOGqgloWBE2KPpmIq8YVjdVVheFVVoFcbd4ZlOIZ6mIdomIZPRWNsmHUh9lvzd3ks4VV16FR3eFlw/0haexiJfiiJeFiJpuVbIjiIC5Fdx0VrmJeIdKhXggiCkOgElgiJk5iKp3iJqniJkVVdmugQ2eWCpEZ3iKgR/rWIBDCK/qdXpuiIByZvMpFedBaLGxNiS1CLKCGHCVF/jvh/rcVxQ3FfxWiMx0gTcuhfAEYQJnZYfOUExaaASOFg1qiFt7iM5+gQzlhjvAWOxsYVHCaO5WgQRkZp6DgR/rVo3TgQLgBkQrZiWDiPTLhpb4hmnwgRiWaQAGBgbqGMAimLmwZea/iDESGR/PhUQfaQOnYQLghpB/kQHWllGqkYMPZaDkmRCVFli5ZYWjaSiQFj9niPKTlqeuZmLvmS6f/4kQYBZlc1kTd5GMyIEWWGaj/ZGEHZg4hoW3Ymj6D4gkWJFEdJhG74AjZZZzwhjU9pFFFZEUzVkVXZE1iZlbaSkyXBVOD1lTsRlmJ5bmRJEmOUaE6FljqhlmsZem05EmP0ho9Yl0Z5lySoZ1TJl5CxlRRBmIJZF4Y5kIdZGYmphWFwkj9Bl4upE40JEQOwagE5jcI4mT1RmQ8hgHsZFJLJmTfhmQ5xgE7pE6NJmjVhmg2xBXIgZ54IFKvJmjPhmtcoELhmm4aBm5vol7y5F75JiMHZl9gInMWJF8OJEDJWBzhYFLX5ffWmeNRZndZ5ndiZndq5ndyJnU3XneAZnlL/RFbiWZ7mKZ7keZ7quZ7s2Z7u+Z7wGZ/y+Z7fYhIFgAQGkJ/6uZ/82Z/++Z8AGqACOqAEqp9lUqAImqD9SVYK2qAOqqAM+qASOqEUWqEWeqEYmqEaaqFIkHEfUQAGEAAiOqIkWqImeqIomqIquqIs2qIjWiYuGqMyaqJkNaM2eqMzWqM4uqM82qM++qNAGqRCOqQ/agAe6hEgSqRKuqQBAKNMmqNe9aRSKqI6OqVWeqVYmqVaeqVGWkshuqVgiqJOGqYmOqZkeqZomqZquqZsqqJdehJJ2qZaaqZpSqdyeqd4mqd6uqcr+qb2+aV8yqR2eqaDGqiGeqiImqhL6qcl/xGnihqkhRqmkfqolFqplnqpjEoSjnqpOzqpW7oFd0AGBMAHl1qlItoFUAAF+okGSNCqVlB1VtCqSIAG+pmqXcCpuJqrKJqpI7GpuiqjnqqlXjUGpepVV4AEXBArO7CsTHACzgoEHRCt0jqt1EqtQOCsJ8AEy7oDscIFSHAFBoAFUPCr5KqovCoSvlquLBqsWdoHVyUIjwoFWnCsZBUEzhqtOSAA+rqv/Nqv/vqvAMuvORCtzhoE3FomsXoFWjCu6tqwbXquIZGuDiumA9Cmp3ZVhiqvVJCsA1AEO3ACZBWwIjuyJFuyHXCtO1AEZcIFVLCwE/uyWwqxICGxMEui7P+KpX9AAGRQBm6Qp2mABcdaJjbwA0PQAfwasiWbtEq7tPraAUPwAzZQJviJBWlQs1arpDL7oYB6tSV6s1fqtVraBQaABGXysUbLtGibtmrbrx1wAgeLn7fKtXK7o1mLpFs7t01asWwKtlaKBVTwqjZwAme7toRbuGrbtlFrBVSABXjbuC1atx1Bs1fLt1JKuUFKARSAAyVQA4AQCGIgBEEABPlquKRbumibA0AQBAMgBlSQB5jruLBLopDLEZJrtZYrqHr7BXDQs0SqAplbAjBgASZAEBFwAA4wAKFrusq7vGibugPgAAcQAQBgAhYAAyWAAxSgArF7tbO7EbVbs7f/u6RlortOVQY9igIUEAIl0AIWgAEKkQANMAA2MASjq7ZIy7z4u7Q5MARR2wAJcBAYYAEtUAIhQAEosL3l2r0a8b0wG75K6mlXRQYyir7qy74QkQAKMAA/MLiEe7/5+8FJ2wE/MAAK8L8MwQMDXMAHjMCVqsAZwcAv68BEWiZxEKUpir44UAPtSxEQkME/4AOm68EgPMQj6wMjrAAQEBEBXAPYu8IsHKgujBEwPLEyPKTjO6wkmrk67L4X8QDx+8PLK8REPMYAa8QD0AAPUBFLjL1PnKdRfBFT7LBVLKRlQggEsAdjYAd+sL7DyxEVsAA2wMFB7FVkXMgj2wE2sAAV/6ARJjDABtzGavrGFhHHDTvHkDoAOlACO/wRXjwAJ2DIoBzK/XoCZ5zGHBHAJaADTgzJWSrJ7Ha3c2vJPUoB65uYDyABRZAEorzLopwERSABpvwRjVwCFMDKXHqkkQvLcivLMzoDIVADPGB5InHLNlC/vHzNZJwDNgDMJcEDNRACM2DMi4rMtKvMXMvMLKoCONACfUyPfzQFXtAGBAAGGUHN1ozN+DzE2szNJ9HIOKC94gykrkwRlKyu6Hyi6twCXEyckKgEGaEA1TzGYpzPhazNCsASGNAC/xzQPDrQE1HQ5XrQIprQC90QTCXPTpUFGHEAQgDEEk3IausDz6qvPv/QAbrctB2QA0kgraNb0y4drfvatoLLr0nwrPdsuD4gBAfwEhm90Rwtox4tESBNrszszDBQ0pb5R17gVQ5dEQ+wAENQyBNdskDQsVFbzTmgskZLykEgAAdbJkAgAKT8yQJQJvo6wjagsj9w1/LLrTvAvEOwAMHM1DAAzk/NolEdEVP9q3NMAdAslO98VUdABBbBAUVgyGNdxB2br0OgwQKQBB37BJvt1gNg0wMgBHLtyfpq12Xd1gKgutAqv/q6v/hbBBxgE95czId9ookNEYutq+HrzApNgyGmBJONERLABJgN00zb2cotADlw2vra2WVy09xqtHZNyh9LygPw2gP/8AT6KtpB4ANCywTgjb9MIAE5kdGGvdsi2tsP8du5SrkqUALR7BFRWdoUnbRzva92Dd1CMAB/ra/c+gOqu9fcvSqkfbYdIOAC8AQqWyZ7zbwN3hM8UAIA/dTw7RDyjate69jtbITImXU3vd8jK976Cto2wNcBHtekbQMfm6/9XdfdzQQDENYC4Nw9XdbdTeEDIL0+YQI1oNvivOEN0eGcGqw6cNVl6WtEcNwTod8mTrJRewJPELXgXdY7kANCIAS6fN38OuN2ndRCAARA0OU1XQRF29kDvrwVLhQYAAM6YMxGzhBIfqmRuuRYjZdr9uROdQSFKchT/q858AMBbgPg/50EaP7g8psDYL6vYt7jSaC6yKvLPhAEAS4EP3DUpPvmRBHnc/7Edb4Qd26pdkoBTB6Ha3YEXkXZEpHcy31Vgy7K6Z0UcU7ksDvqClHqlTqmKlADIa7qBkEEXgXoEmHZse5Usx7Kts0UQp7heKvrCcHrlFomM4AD9/0SEsbqBADlEfHVOP7Ssr7shRzYg70UPIAD4Ty30o4Q1H6oYqArDqASxyvvAvHkrk4RLO3SRJzZ5L68Sb3UUtECISC37X4w5vyyBqArE6ASEwAsDb8REM3pzOvv/166Fm0VGFAD6w6zB28Q7x6oITAHuaLeKyEBJd8R9nzxLK+0+3zuVGEBBf+v8OTsvQlfrjNQA1wcv7diwiqRALni8xux8i1f9AD78lyx8R2fwDW/wDevqzrQAgURAbdy0S2RwbFi9R5xy7ls9F6/r77Mz17RAriuqx9vH09/qSgQAsE+EBsQK0ncEhBwK3HPyfFL11/f8qSMxmNhAiGwypx69lCT9pQ6AyWw5wQB9KTSADDB82XC+CPxx4GMvxaf94ecyItsFhhQAktvqYKfRYSfqDMAAw6B9T8OE1RPKkA+Ep0Mxspb+Zb/r2bM92oBA53/qJ8/MaFvqBQg9Q/x8AMg8DBxAGUi/CXRwxrM74YL+7G/r2aMxG9B9p7f9C+8+3tKARYwEQ4g2DL/8dXcnxIYrMGCnrbM768NLgQnoPxTLsIkLPRvYQFlf6i5vx3Wj6fYXxETYPzDr/8oARAQGgywMSSHAIQJFS5kKIDAw4cNJS7sMMDigB8dJm7k2HFjjiE2BjSAAMDkSZQpVa5k2dLlS5gxZcq0QCHATZw5de7k2dPnz58GCswk2rKAAaBJlS5lmpOChaJRpU6lWrVlhAMOBgQB4tHr14QnLl600RXsWa9AggxwcCCCVbhx5cat2dTu3aRC58Y8itfvX55P9w4mXDhmggYLtgI5iNZx2LFjhZzw8dhyDrUDFjRIYNjz58F1AY9mqhc0yr6kVTOdAeP0a9hxKzTQauOE/0bLYHdE5p0xt9cOJ0Q6aFAh9nHkMWHMWN18p2nYqZ1Pz4nCdXLs2V9COKDA4o7bvznu5s27rHiGwckrOFBS+/v3MFBQbw79tXT6zktggN/fP4AHKujOIht+GAI3hCCKyCsfOhjihLXKk9CGIE44sDK0HPxBpAHYM+4/EJHDoIT8SLPvNPxKHE0HE0J0Eb4EOGhAAouKAE9BAjbyAQgmyJPwRyB3YAIIDNMD4oQdirBIggY46OxFKGMzQQcV/ToRtBSrvGsGqKL0UrsYM1AAxwpv6yCHHYMQorwFFKARSIuKO+CADRRQjDchygzCRwcUyMDJLwONzQLmtCxtqNiyNP9UKRRKEPTR7HAU883y/JzgSQASgFMB91RKYAIxJTwAU0hLPa2E+RYF6srPFFXVJxZNlfU1HLHSaqwNOOg0pQN+dIDU7TjYILK23pr12MGmfNUnVj1zddnqWkB22s8m8O4iBzL40KVeeVuAA6pmu9UiBSag9tyqWkgVWpyaNexZdnHgD116rXogq4s2A9ala8c64IG4ELuTrX/rNRgmDHBgt11Eo0NqYZ24PHhiou4duNyo+h1gA2P3sjbfgikW+SRCF3a3MHhV1WHekVtOyeKLSJrqIgX23UsgkAF2eWIMqIT2ZMJS1hIFaXc2GoAJxsVRKrbMfS2CgSxywOmj61X/d1mgBxNaRQparLplCPptIIKlo2pA59igpnnXr6c1wSZVs95r6/wcbXvkbjt0r2xIw77ogLvRJXFRueeiezoUugz8YAjeXIBqAPgudYI7JWB7cVMtWFfFwuU6vDkVWMacXsot2gBtkyQv9YFhNYN89FIxUEHLzuP6XLUQYK/3gagX2JbiCu48W3dZQ6iydrhuH+064ql94E0JOh45gjfbsrl5KGHgvOH7Hh6aB+ypheDODL7OYKypW9IsA+mneiABTOGXP4EIIpC/fex52Nw55K1SHi8VgA9S77ueVPykkgdM4AAcwB9K4Ic67YzPIq8z2gSIRcFMJa1DGJzJ+Qbw/yHezGksDQgfSngwO+r0ryr/s0voTOXB373EO+pTQEokeJGWVMAi5YMPBCyygAKeRHXTSkDl3sSefWlwAeyTyq1ImKkE0MhJWBnAv7RyuebJLoXcQ5H38rMyWTnxJIhRgMwSUKcMvE8ro+IA4ACwQAB0KCVaAVcEeMgBBWxgW1FzQA/vhEWVDHFaElxASfKWvpRocINE0SEHFIM27zypV4CLZAlR0rPpqJAqLFxK7mTVyEdmagAS6M4BdLiB822gdOUaCAR8SEI5nsSHEkjJ+TIwLOM8YGO4tMqSmhREldzwiTAR5CAVU0gANC4ywzSJBS1ClIGojWqVfGOHztdHS/+mxHj14SKWvDgdT8oqmgMx17CMFYFhzUkrAJihKDNwvpLE0iSaqiFKFkBLXW4AaQOYgAWZyTTeIPElERDeTIppTM0YC36K/NE/W6LLDmmFliahZq/6NLZsqmSbqtHkVDgJlHCaCqIKkCg7B4AS78xpTiY9iQMW4ICJyhMAEdCMzt4SSznSSAJvgmBRYjQjbxVnJVEbCVEOilAJ9BQlilyAG2PCgZHMSTHuqWgVM9qSjY6mo1L5qE9CaiqoNkCqA4BAWBMwJ6huIAGzMWkFDGkRcMWxnicZSFsSAwBc9kpXHZqTFOdyVo3BKa7hc6Y+V8LQNBKFRjqzJUUHIEmrXpX/JVn9y1aj0lWefNVUizVJY/HluzfeSp/BG0AdLaIzmQIoA8ckIevWB4DzfUiHEx0MYHnTJ4s4tYTdGmwzx8UxyWqHsnixbFEwqxPNBk6HDpWVD1NbwmvtimbADO5phmuX4hLluDhRQfOGRd1A0WgBSsXeAxRD2zgisrrwQaGVutmqbwLGhet9VLfAu5KjoktTkaUviLTo3uNsFwVe6++XaFrUqeQXXVFrYIGzY4L9HSrA8fWLAB3sJe+MlyoKPpd5n3vh7PAAwImi8F2YB+IX7be3UeHwuaD6WBT3R3t3ye5MMJvcGPvHO9jcsIKOppW55jg7113Ve51VYqbMV8gg/9ovByXrzPsumTD/lTCJAYMCC0vZP8PisYO1YlgtI0d/TamxTD5agzD/58BODm7rGpxmz9SAzEZ+F5KTQgE4+6dXGgbxrXSb59PATSll5oudfzJgQMNHK8xlsY+P5swuJ/ozEF4KoWHCQrtJGjvOBWRRWkyvi3Ra03MZXF7ojDJD92QGo86OReXy6QXnFiVNY/VeClXkCeNFcceCiCVpxOhG97oqEEgAwOwn6s4G+TjDQm+3JBDlWrvEAoM+ddBSvRM8U0vY4bNIDHu87alE0rzIlOFJsaNDBJskAtdSwJujLRNBM6vaWru2TgiMLHATb7/uzk4kvWMurKwV4A0oY/9JvFOBMgLsAWJiz2cOTOuTlG4k5H03TExg6lw3BccVN4yrX+Qd7zxRU4pp9z0PsIAFmLQBqQSASw+QgUgTRit3Ui/vfhgylkSgjRPQ2QPayAGKzwR+6qZfzufEZooRmWEZZ8q9OQ6agSj7P/2Kq6buGFV/m5tGAEC5WPkNl5ATdTMfSsCtXOJMciUT5RlG9jw5+Mxq/rmZbNFp0A928aDMe271vokOnh6blELJO8NCpqbc2Cuxzmnd5p4hBDYw869XpVc1nM3AeHMVzXSGOy0nazLZEpPusATuk1QJTR0AsLB+zWc9sfRLPrfraeVbd4pZcVVgvZJIni+phjfJLCv/kIAM+C1GG2PnpbzT9qpANeUpURu5nAxVHvZ+lCehUdtDv5LcDkju0DeJLpd/tGnLm+lJ6S69ZA87i0D7JbdXSSV/zXuTVAB6iyc5wFqnXsPs14HXWiK/ST9GeaIm0YsMYAkhlfi/ODK3qmmv59A7w+G7E9O2hyih9JsL9jsX/UOaW8GYmLCguYoA7zuJR4IArXAAtoGfGXmglBg9q/Kg8jkl6UMvo5kxnmg9lzgc0fk70KjAV3O0r8nA9Yk8lAAyOqmhVDqjASgfYnuAPlmJ61MJFgQcnoOqzqARU6IRb3MZDBA/K1MKv9NB2LAIIYyJC6SWDKQKdJKauMKXtpgj/+YClQE0CQS0oLfgnfPKwp1ZPZ2wQaOotwgEQ8+wCORbrzN8jcQYw+1YIuyhwT10QM+ptxyUQAKgQBirFzHJjkL8DN4xQbkoougjni2sQUe0nWvLtno5v9HhQXppp+TIRM/IGwWsCn/Bnnhbui4ECjQzGFTEHFV8EZ9TAAXgAAF5CwUCmAlAowdoJ6gpuNdwRUCECzlrwPHzCdh7xsJAt9r7tgkEuyRcLQsCl5eqpg3IigSYIYIiJZR7DaiKOWusivBrxGnsiXaEOlnrwV2ciVdSN/OSgEbiOmx6gGQ8qbAaEPWTismbx7kQxXjENoT0jDuROm2cRKuAP5MYCM6Sqf8ZQjyVQsRwS7eGrIpaDAA+ZAmhwYGJuce2QTt2TDAfrAqUqwD5EyXiw6vSOqNyPCnfA75BrIo1+ki4UBh4vEWfyLRT3EbimTkxtEejHLbWqSet+BA7ZIvFi7/5A40DK0ifTIlSs0WHSYpqPBeUrJqocSY89MXPcxFnArasjIl35Mru8cq1jIu6KraQgxSokrv+IKq4nIq2vImRXAmh2UurGEs5PMscO6Z0S0LBjAlpFEp5XEypqCuq4bQc47QJMgmtwMqGbMyuBAqKCcvPUMH36RhiI035QRv7USjquiCVWLS4KMNjqSsAkE1ROj3IbAnOfEvPPMmlTA7TESU3gij/2tIYHvo/uHMJbOGgPbM7MmxJl/EwNxqIJxqIT7xNlMjNLkqKz+xN5LgI+IkstDMWcRsIwDHOWETDy7QK2JQVZ+oY1/QwzWxH7PQmoFg1QBull9IhN5KAb1FMk+oMmkq5yROh86QKLoOL9TSVL1uqONkn27TO6wzKzvyJRNugDrEqmhqbs6SmZ4LF45zI9IzIR+vFaioq76hO65xP+NLO+6yhawGca7oW46gk04s7k/hQq9ixCwOylVCmtiDR21TRI2PRgwHNQKyh/QKcl5qTYdEn7xBGLLTRBPwruCqwF8OUi5CAMhoXtmBOnxTSOiNSXeTO44gl8tQhHoKogFyS/w8xz73IMC8lHg8LMjgp0JUQzaLrvTxNptPkFbwEMTBFNbgsUjLFngNTy/BhsIqBid+EP+E8CeJEiZVasr4UyVFMnlT7SgidCvtiSSNFliQlDO+Ev/B0rGIjzxKtxxir1L9UCaEhyk21CvGK05RI0C/xMBmUC/x0AP00Cf7kvv+cKc04iUkVsq30y0v1n1QzyViNC+eCSGJyzoOJrsKw0MDL0BoN1imVwz91MKDMiVZNCaExxaKUSIMq1JF5sW5tCVuNEt4yDDl6UdhiCxkN1mxNs5AMV9S4Nt40V5ZQAqP81HppHaQLJGklnd+EVySVtSWlE+J7Uvn7oDxTSMfsCf9NxTd0TZ2AzViReR7N2Emjca6kOtKKrCI07b7T6hd+zLNKtdSF3IlcdBmAJQAwMIk14NijIaiPbR5C4shmNYlolFDdBApyHRmIUAKTIAIlmAKePSaQFRlCetqfNYmQdNmK7YlInJibJYAsyKioHZ2vndqiCMVAtbal+MPY28ZBSNojIAKm9dqBiVaB/ZIi2lmxLQpGBNdkXaF6+0Lzm0CAfdv1Eqb1O9hZcSZyu1ui0EO9fVmeyFpee4iZPQI96C8SlBona1f48CBOVFyiINuypTemQFtqmVmkLTCPbVD8MlxIoZ4loVXPNYm8bdyr7YnyOxglOF0Hs7luW925DRH/0vLI2JUJBhTa7GSKix1eaLqI05kY13Id5SWKlnXL410Kv5XEmhUysSvYyakcqR1exjVe+mwKp4OUI8AR9O1aFIsMTjkXv1HV6JUJvOPCCe2kYyEC9MURL4gxoooZn/WP5tOb+C0KpUNWx/WJ8n2U883fh3iDHHsT2rgIzXU4osK/AY6J+aXfoWWKooUU/GVg3UUx53IArFCMCS4MnLk52L1gAKha8V3Ru0heL1lg9BXcGOsWc7kXHOHe5PgYFWbhopjeFx7Su7hdU/lgHDkDLaPNyFEQzeAM/xAYbAE6II6KW8u7A/4JWDVf9CWCMHPNJoYI9BGq5BCXseDAKi6K/2PV4Oq1C0STFSR+CPXVMmdaCVuJjFz5XqIoq9bBFrdIY6mgNGrL4p/oYAVWkP1NMxy1oQygFJrJgEsJGFAJrFEKPkCmChem2Pq9i5gtlTh2YEXmJ5iIgGO0vHzJozn5vflZ5bViUjthE1X630s+iaAd5NpdCiyblQUOYS2TGqIg5VCpU2F+5AmQ5Vk2oQjD4lteCiXz4Iew4V5+pk+znzaqE0quFFSeomOeCyqrtL3dJL7zKl1W4jzz5RPe5uMoYNb7Zo8KZ58gXS8hAi8uZ1E+Z3R+jdm15U3+iyy75xs1N3v2Z88QMeJiZ65yZ594Y4GOGo39XYHGDkGmMYO+LP+E9olm3mZ0Q9SHhpJuxq6JNq6KtuiFXuSNFpTi9WhCtouNm4qw4WFnRWOYuERr0WN0UQwwK+lHUWeMW2a/WOmooEiWYEUQXdeUmKGzMmZqcSaXxmn40Omd3mfcoVLAEZCSOCM/UaMq0jyCS6yzmg0F+JBllBkAzACC+xCBuOr4y6N1OmoA6Q49Mgk88hOkjpISRJuAZmqqcOqn3mDn8Gmhy+qiOqVUWqViNrl7qqY2EcNzPLnvq80DqL7FPuzZwpdqqsKmqj7qfOz4jBKlRom7xuuo0Ou9bmNwCpgkvCf7qyLKbieoMg546pXOOJ/hEysB5D39bO15dbwBeIuMfCz/H2IP8mzSUaGYEqxV1gXt2BDt0R7f/PBrmBg5lAOYlFIplqrsyobt644qxQNAwDE87Ibtdurt72SPOTnVNylLZEma1/ls5I4J5V5uGC4RMKIKq0srAEirtSKhg3OljSk7AYUx2M5JS56nkYgisvIhtXKpuKuAdcJulLsUDpiAXzqfbNxOh25vuMAk/vlo7QrpprhoouC9Jw2t3yQtcNEgy7Fu7I7YUeqYkYNeDRylkghIB2hwGNNtthCQY0JRDAe0juYoDrcxD//wfu5xI7eKE6IPfT2J7UqKXD5yKKeKMVPyIDezITexZsWKA1jqKIeNfOamlO7rTbUgmBqlOGXv/yN/b4kOc+cA8bU0PdQTXnY97i6Xih/fIjZ3jsSBTGANwea88DpfCc0xlCU3iSa/iy32SQQkad/F2UCPiTUukUIHgEO/i64JzWIDkD0tTVnqU0kl6pGBQc+jpVUiLzTH67d5lUmv9LsgmkAkPkddEkgdi08s1ruxwog1jgqIAB8C9UdPl2TenjyXb8jtpfQj1YsQz8eyufKcxbuJypU9CZri8l+XCQ3HmiovNIiJGBlmGv7k1cj6Vf+k0WHlVkt6nlytdrgoGXZZ9SufDnnZC2vF0JHIVg5VQFsnHupRgBVWd5dImG13923nCVfXVReVtRjtXXJfyebpF2g99Xu+mv+Az/ZLe3f6iBW4kKNQbdgmNSkoldgcg/hjVpaBt1qoLvkAaJSMr6cz9U81VVn0pi+Rv2RUQXmT52ubxwmJadaZr2J2t3mBz/mewHgI7fkLJnmhD3qh74n98Pe7HZGlp17mjvqdsA6n/1n5oHoD5umob42rt87l0Hqpj2+xD4xu/3pAFI2yv3nSXnudEIy1NHqxVXu3V3q37wm4/0i5b1a6v3u7v3u8P/uK23sI7XvA/3vAx/uiaUfCh8wWyOS6p3jXs3ih93prbPy9DPvE12Sc33yfmIGmR/s8G5Er9nzaPXnTJ/gQSGDRBzETCIFgT33ET32iXfzWv7DHp31lRn3/3Ve1Gij22y8hDKiB0u/9IQ5T41dpwRcyzAdDC1Bzz5/95E+KGfh9TWt+jhv+4p/+0N077u9p208z7I+2FoB+3Zf+71eKGcCBImd+OldcHsCB7U9/zm97+v/wGmD9Cxt/QAMIEzVUBCho8CDChAoXMmzo8CHEggYKAKho8SLGjBo3XixgICLIkCJHkjRIAQYGjipXsmzp8iXMmDJn0qxp8ybOnBkxwKBQ8ifQoA0n6nTpUSjSpEoN6kBZ9CnUqFKnUq1qVSVPHUu3cn1I9KrFo13HknXYNCXYtGrXsm3rtmLWsnLJfk0rdi7euRRqmHjr9y/gwIAF+sxrWGldsHcP/zPmqqIED8GSNRKoXHky5swXeZQg2Pgz0MRXF4MuLXRGiBZoNf+1fJk17LcYWoSYYfr2SNFWSePuTXJv5NhsXRMQbvwqjxqFfTP3SlEt7+bSIaKG0fd4VeLYt+s0AaP29PAMdVeNLv78QhU4VHN/qr09/JezcXhGb98gearm7/M3qJ59fAEKKNV89fXHX35T7Xcgg/9dNyCEEbZkQgv0MXhhAAlKtSCGDKJWQ3ASighhcuB1iKGGUXF4IoYUlNDCgyPKyBqFJSzHYocpQrUijh2ioEMJFqwW33sz+jWbjSj0uKSOT/G4JIsouAhje0UamVaNFCgJJZdNFvUkl0tSgP9DDUIKZ+WVUWFgQQ043BhmmF7qBCacXEpJppmToZmmTWu2qWWdgR4kZ050CgqnlCG8aEFrrvFJkwUtlBACoIdait9zdn10KacPJbrokI9KtqaklG7ZKaoZZqrYpqm66pAKY5YAgwUxikqVCRbAUIKbBr76KqE4GfrrrxTIWmatt8KUK5u8GksstAsFe9Ow0VpbUKyyzmoBtzJyq2sJzlLg67XlIjStTdWau65CxhpLHLLfJjsVs/LWEG64lLrLLr8hoVuTuv0KXBBxAxuM4qqjtXowww4V3DDE5/1LU8ARX/uwxRn7NvFMFWtMLMYfi/wZxzJ5PDLKKascUckxnbz/Mswxr9wyTC/LfDPOEdP8UgFIGPAz0EELPTTRRRt9NNJJK7000007/TTUUUs9NdVVW3011llrvTXXQCORsFUMFDA22WWbfTbaaau9Ntttu/023HHLPTfddb9NnN1567033337/TfggcvNgLKFG67SnocrvjjjjR+euOORSz455dhBXjnmmWu+uVWXc/456KGLPjrppZt+Ouqpq7466627/jrsscte0QgIzITACDfhnlHts/v+lue/wwbCcwPY7pLxNyWPEfHCO59W8M+3VQDxCIDAwgUXfABA8yAMoEEBJAAgAwIXiGARCBfg/oHx5K+w/fjlnw8A9e7DXwACKyRP/zwJMpDQPABEoD4ZVERsIlgBAuYnvQXCJHoMTMsABpACD3wvBQNYAQAQMAAAjGAAHkAACzo4ggsM4HwFGMAFCqABBkQwBRq4IAcHMMISAqCFL8RgB1OYPA1SkAEaDCAKRUg/D2pwAOJ7IBIR56gk/iV5JyTcDjdYw+N5IAUAYN8FAOABDVTkA+yz3Re1aEUsTvGKydtiRaIIvx+ScHsTHCLhOkg4JtLxIg6so1ScOAAo2u6HZfxj8paXxuMFkpC2W14hB5lBKS6ykY18IhzxKMlJ+kWPfHTk9xhAAhKK4IQEJKEMGHABFhoSAJz0JCD7WELvqdIiP5TBAAogAhRGEpuSlLwlLq1iyTL68YQDYMEHSOiB3F1xBRTUAAkQCUZhElOZAGDBCzXYyor4cQQU1F4t95jLbXKzm978JjjDKc6o3HGc5jwnOtOpznWys53ufCc84ynPedKznva8Jz7zqc998rOf/vwnQAMq0IEStKAGPShCE6rQhTK0oQ59KEQjKtGJUrSiFr0oRjOq0Y1ytKMe/ShIQyrSkTIuIAA7);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Simplified schedule demonstrates the aerobic metabolism of glucose, lactate and triglycerides in the mitochondrion, with a central role for OXPHOS (oxidative phosphorylation) system. When this system is blocked (dotted line), accumulation of lactate and triglycerides occurs, while formation of ketonic bodies increases.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Kees Brinkman, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_62_15343=[""].join("\n");
var outline_f14_62_15343=null;
